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Acute Lymphoblastic Leukemia  
 
Acute Lymphoblastic Leukemia (ALL) represents a biologically and clinically heterogeneous 
group of hematological malignancies arising from genetic insults that block lymphoid 
differentiation and drive aberrant cell proliferation and survival. ALL is the commonest 
childhood type of cancer. Today different treatment regimens result in 5-year event-free 
survival rates that exceed 85% in children (aged 1–21); however, relapses are frequently 
associated with a poor outcome and for this reason ALL remains the leading cause of cancer-
related death in children and young adults (aged 21–39)[1]. In adults ALL is less common but 
the treatment outcomes are significantly inferior to those in children. The reasons of this 
difference are not fully understood but, generally, are due to a reduced prevalence of genetic 
alterations associated with a favorable outcome in the adult cohort. According to the 
phenotype, ALL is traditionally classified into precursor T, precursor B, and B-cell (Burkitt), 
which are then further classified according to recurrent cytogenetic abnormalities. The 
development of microarray technologies to profile gene expression and structural genetic 
alterations in a genome-wide and high-resolution fashion have revolutionized our ability to 
identify genetic abnormalities providing important insights into the pathways deregulated in 
ALL. Moreover, recently the development of next-generation sequencing (NGS) technologies 
has provided researchers with completely new and effective tools for the discovery of novel 
alterations, depicting an exhaustive picture of the leukemia genome complexity. ALL is 
characterized by gross chromosomal alterations and in particular by alteration in the number of 
chromosomes (aneuploidy) or by chromosomal rearrangements that either result in the 
expression of fusion genes, or deregulation of genes by juxtaposition to strong enhancers[2]. In 
ALL aneuploidy is relatively frequent, reaching the 20-25% of pediatric cases (hypodiploidy 5% 
and hyperdiploidy 20%) and 10% in adult patients (hypodiploidy 2% and hyperdiploidy 8%). In 
both adult and pediatric patients hyperdiploidy (>50 chromosomes) is generally associated with 
good prognosis and usually isolated to specific chromosomes (4, 6, 10, 14, 17, 18, 21 and X). 
However hypodiploidy (<44 chromosomes) in ALL is generally associated with poor outcome 
and with a significant tendency of progressively worse outcome with decreasing chromosome 
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number [1]. Chromosomal rearrangements creating chimeric fusion genes are common events 
in both children and adult ALL. These chromosomal rearrangements involve crucial elements of 
the hematopoietic lineage like transcription factors, epigenetic modifiers, cytokine receptors, 
and tyrosine kinases. Common rearrangements in B-lineage ALL are the t(12;21)(p13;q22) 
encoding ETV6-RUNX1 (TEL-AML1), t(9;22)(q34;q11.2) resulting in formation of the 
“Philadelphia” chromosome encoding BCR-ABL1, t(1;19)(q23;p13) encoding TCF3-PBX1 (E2A-
PBX1), rearrangements of MLL (KMT2A) at 11q23 to several partners, and rearrangement of the 
cytokine receptor gene CRLF2 at the pseudoautosomal region 1 (PAR1) at Xp22.3/Yp11.3. T-ALL 
is characterized by activating mutations of NOTCH1 and rearrangements of different 
transcription factors like TLX1 (HOX11), TLX3 (HOX11L2), LYL1, TAL1, and MLL[3]. Different 
somatic genetic alterations in addition to gross chromosomal alterations are relative frequent 
in childhood and adult ALL [4–6]. The most frequently mutated genes, particularly in B-ALL, are 
genes encoding for transcriptional regulators of lymphoid development. These include PAX5, 
IKZF1, and EBF1 that encode DNA binding transcription factors required for lymphoid 
development. Among them the most frequent are somatic deletions or sequence mutations of 
PAX5 and IKZF1 genes, while less common are translocations of PAX5 and deletions of EBF1[5]. 
These somatic mutations results in loss of function or expression of dominant-negative alleles 
and impaired lymphoid maturation that contributes to leukemogenesis. Several other pathways 
are frequently altered in ALL and include tumor suppression and cell-cycle regulation (TP53, 
RB1, and CDKN2A/ CDKN2A); cytokine receptor, tyrosine kinase and Ras signaling (ABL1, ABL2, 
CRLF2, CSF1R, EPOR, FLT3, IL2RB, IL7R, JAK1/2/3, NTRK3, and PDGFRB) and epigenetic 
modification (EZH2, CREBBP, SETD2, MLL2 [KMT2D], and NSD2 [WHSC1])[7](Figure 1).  
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Figure 1: Prevalence Chromosomal rearrangements and frequently mutated pathways in ALL 
across age groups. The prevalence of the different chromosomal rearrangements and the 
frequency of somatic mutations deeply vary among the age groups. High hyperdiploidy and 
ETV6-RUNX1 are each present in 25% to 30% of childhood ALL cases but occur in <3% of young 
adults (age 21-39 years). The BCR-ABL1–positive ALL comprises 2% to 5% of childhood vs one-
quarter of adult ALL [3]. 
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Overview of standard treatments in adult ALL patients  
 
Progress in the treatment of ALL in children and, with fewer efficacies in adults, has been 
remarkable, from a disease being lethal for decades to current cure rates exceeding 90% in 
childhood. More specific diagnostic procedures, like immunephenotypes, cytogenetics, 
molecular genetics and large scale genomics analyses allowed the definition of new ALL sub-
entities which, in some cases, have been translated into novel specific therapies [8]. Despite the 
above mentioned improvements in the treatment of ALL, several leukemia subtypes continue 
to have a very poor prognosis. In the treatment of adult ALL patients, both national and 
international therapies are chemotherapy-based, and are usually structured in induction-
consolidation-maintenance [9,10]. The goal of these therapies, and in particular of those 
related to the induction phase, is the achievement of the complete (hematologic) remission 
(CR), leukemic cells not detectable by light microscopy (less the 5% in the bone marrow), or the 
achievement of the molecular complete remission, minimal residual disease (MRD) negativity. 
These two clinical parameters are usually evaluated within 6-16 weeks since the beginning of 
the chemotherapy [8]. Based on pediatric-inspired therapies, the overall survival of standard 
risk adult ALL patients has improved from 38% to 50-70% with chemotherapy alone, and the 
outcome for high-risk ALL patients from 20-30% to more than 50%. The actual induction 
regimes are modification of the Berlin-Frankfurt-Munster (BFM) regimen for pediatric patients 
or of the hyper-fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone 
(hyper-CVAD) regimen. The first regimen is an 8-week induction consisting of vincristine, 
prednisone, daunorubicin, cyclophosphamide, 6-mercaptopurine, L-asparaginase, intrathecal 
methotrexate, and CNS irradiation[11]. The hyper-CVAD regimen is based on two alternating 
chemotherapy cycles, one of hyper-fractionated cyclophosphamide, vincristine, doxorubicin, 
and dexamethasone (A), and one of high-dose methotrexate (MTX) and cytarabine [12]. The 
goal of consolidation chemotherapy is to eliminate any remaining, subclinical disease at the 
level of the bone marrow. The agents used for the consolidation phase are the same of the 
induction phase. There is a high heterogeneity in term of treatments, but mainly all the 
protocols include high doses of MTX and L-asparaginase. The last step of all regimes is the 
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maintenance chemotherapy whose goal is to maintain the remission of the disease and prevent 
the relapses. The common regimens are based on daily chemotherapy of 6-Mercaptopurine 
and weakly doses of MTX or vincristine[10]. A side of the conventional chemotherapy the actual 
treatments for ALL patients are based on targeted therapies. These therapies specifically target 
tumor cells that harboring particular genetic or genomic alterations. The introduction in the 
treatment of Philadelphia-positive ALL patients of the tyrosine kinase inhibitors (TKIs), imatinib, 
against the oncoprotein BCR-ABL1 have increased the RC rate from 60-70% in the era pre-
imatinib, to the actual rate of 80-90 %[13]. During the past years novel TKIs, second-(dasatinib, 
nilotinib) and third-generation (ponatinib), have been developed to obtain faster and deeper 
molecular remission and to target mutations that frequently occurs during TKIs treatments and 
that are responsible for treatment failure. The targeted therapy is not limited to the use of TKIs 
but includes also immunologically based treatments using monoclonal antibodies or activated T 
cells. B-ALL cells specifically express different superficial antigens (CD19, CD20, CD22, CD33 and 
CD57) that can be routinely used in cytofluorimetry to define and to confirm a specific 
diagnosis. Due to the abnormal expression on leukemic blasts, these antigens can be used as 
targets for specific therapies. Anti-cancer monoclonal antibodies (mAbs) like the anti-CD20, 
rituximab, can mediate anti-tumor effects by different of mechanisms including signaling 
against proliferation, direct induction of apoptosis, complement dependent cytotoxicity (CMC) 
and antibody dependent cellular cytotoxicity (ADCC). Other mAbs, called antibody-drug 
conjugate (ADC), can deliver cytotoxic compounds on tumor cells that specifically express an 
antigen on their cell surface The inotuzumab ozogamicin, anti-CD22 linked to agents 
calicheamicin, is an example of this class ADC[14]. Antibodies have recently been used not only 
to selectively kill tumor cells but also to stimulate the response of the immune system against 
leukemic cells. In particular novel bi-specific antibody, called BiTE (Bi-specific T cell 
engagers)[15] like the CD19-CD3 blinatumomab, have been developed to enhance the 
interactions between CD8+ lymphocytes /NK cells with CD19+ leukemic cells[16–18]. Despite 
the great response rates with BiTE or ADC strategies responses appear short-lived and most 
patients relapse. Novel therapeutic strategies using activated T cells showed a more durable 
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response[19,20]and today, CD-19-directed T cells, modified with a chimeric antigen receptor 
(CAR), are one of the most promising technologies for CD-19 expressing B-ALL patients[21]. 
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DNA Damage Response (DDR) 
 
Despite all the above mentioned therapies, tumor cells respond to the genotoxic compounds or 
more generally to DNA damages, activating different intracellular pathways in order to 
survive[22]. In the eukaryotic cells the mechanisms of response to DNA damages is generally 
termed DNA Damage Response (DDR) (Figure 2). The crucial function of the DDR system is to 
maintain genomic stability and prevent transmission of incorrect genetic information to 
daughter cells during cell division. The DDR system includes different regulators involved in the 
recognition of DNA damage (DNA damage sensors), in the recruitment proteins on the site of 
DNA damages (DNA damage mediators) and in the response to DNA damages (DNA damages 
effectors) [23]. The most important consequences of the DDR activation are: i) the regulation of 
the cell cycle, ii) the activation of the mechanisms of DNA repair and iii) the induction of the 
apoptosis. 
 
Figure 2: Schematic representation of the DNA Damages Response (DDR) pathway. DNA 
damages are sensed and repaired in multi-protein complexes. Signaling caused by this damage 
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results in the activation of different mediators of the damage response and then results in cell 
cycle arrest and a choice between repair or progression to apoptosis. 
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DNA Damage Sensors and Mediators 
 
The first step of the DDR is the identification of the DNA damages. Different deleterious attacks 
from extrinsic agents as well as intrinsic sources, such as reactive oxygen species (ROS), can 
induce different DNA damages. One of the most deleterious lesions that can mine the genomic 
stability are double-strand breaks (DSBs), whose high cytotoxicity is the basis for conventional 
genotoxic agents, such as ionizing radiation (IR) and other compounds, like the topoisomerase II 
inhibitors, currently used in the treatment of different kind of cancers[24]. Three kinases, 
members of the phosphoinositide three-kinase-related kinase (PIKK) family, the DNA-
dependent protein kinase (DNA-PK), the ataxia-telangiectasia-mutated (ATM) and the ATM and 
Rad3-related (ATR), have relevant biological roles in this initial phase of the DDR. In particular 
both DNA-PK and ATM are involved in the response DSBs while ATR is mostly involved in the 
response to DNA replication stress and in particular to damages that involved only one strand 
of the DNA structure (single strand breaks, SSBs)[25,26]. The Mre11-Rad50-Nbs1 (MRN) 
complex is fundamental for the response to DSBs and for the activation of ATM. The principal 
function of MRE11 is to bind DNA and, thanks to an exo- and endonuclease activity, to synapse 
DNA ends [27]. The main function RAD50 is to maintain DNA ends in close proximity thanks to 
an ATPase activity [28]. Finally NBS1 recruits DNA repair and different checkpoint protein (ATM 
itself) in the site of DNA damages [29]. During normal cell cycle or more generally in absence of 
DNA damages, ATM is an inactive dimer. In presence of DNA damages ATM dissociates in 
monomers and rapidly auto-phosphorylate on multiple residues which are fundamentals for 
ATM stability and activation. ATM recruitment has been shown to require its binding to the C-
terminus of NBS1, an interaction fundamental also for the kinase activity of ATM. When ATM is 
associated to the site of damages, it rapidly phosphorylate the histone variant H2AX (ser139). 
This is a key event of the ATM/ATR transduction pathways and is necessary to amplify the signal 
of DNA damages and to facilitate the recruitment of different mediators of the DDR.  
Single strand DNA (SSD) is physiologically generated during the duplication of the DNA. Indeed, 
during the S phase of the cell cycle, replication block is generated to allow the polymerase to 
duplicate the two strains of DNA. The first event for the generation of the replication blocks is 
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the activation of the replicative elicase, MCM (Mini-Chromosome Maintenance), that ahead of 
the polymerase unwind the double chain of DNA, generating SSDs. Different insults can main 
the stability of the replication forks, like the exposure to UV ray, causing the break of one 
strand of the DNA and, consequently, generating SSBs. In the contest of stalled replication forks 
or during the resolution of a DSBs, specific proteins, termed RPA (Replication protein A), bind 
the SSDs. The activation of ATR is strictly associated with the constitution of the SSDs-RPA 
complex [30]. This complex stimulates the binding to the damage sites of second critical group 
of protein, the RAD17/RFC2-5 clamp loader complex. Consequently, to the site of damage is 
recruited the RAD9/HUS1/RAD1 (9–1–1) heterotrimer that in turn recruits TopBP1 which 
activates ATR[31]. Once activated both ATM and ATR regulate the cell cycle progression 
allowing cells to resolve DNA damages before continue the cell replication (Figure 3). 
 
Figure 3: DNA damages Sensor and Mediators in the response to DSBs and SSBs. Damage to 
the DNA triggers the recruitment of specific damage sensor protein complexes. On the one 
hand, the MRN (MRE11–RAD50–NBS1) complex is required for the activation of ataxia 
telangiectasia mutated (ATM) in response to double-strand breaks (DSBs). On the other hand 
the ATM- and Rad3-related (ATR)-interacting protein (ATRIP) complex, formed by ATR-ATRIP-
TOPBP1, is recruited to sites of single-strand breaks and activates ATR. The activation of ATM 
14 
 
and ATR promotes respectively the activation of two different effectors, Chk2 and Chk2 (Figure 
modified from [32]) 
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DNA Damage Effectors 
 
Different effectors are direct substrates of both ATM and ATR following the activation of the 
DDR. In particular all the downstream proteins activated by ATM/ATR are involved in cell cycle 
regulation (checkpoint kinases) and in the repair of DNA damages. The direct substrate of ATR 
and ATM are the Checkpoint kinase 1 (Chk1) and 2 (Chk2), respectively. Chk1 kinase is activated 
by ATR through the phosphorylation on serine 317 (ser317) and on serine 345 (ser345). Rapidly 
Chk1 auto-phosphorylates on serine 296 stabilizing its structure and creating a binding site for 
the interaction with its direct substrates, the phosphatases Cdc25 (Cdc25A/B/C). The activation 
of Chk2 is enhanced by ATM through the phosphorylation on threonine 68 (thr68) and followed 
by several auto-phosphorylation events. Chk2 shares the substrate homology with Chk1 and 
inhibits Cdc25A/B/C phosphatases in a similar way[33]. In eukaryotic the cell cycle is finely 
regulated by the oscillation in the activity of different cyclin-dependent kinases, CDKs, which 
are positively regulated by proteins, called cyclins, and negatively regulated by CDK inhibitors 
(CDKI) and by event of inhibitory phosphorylation[34,35]. The transition from a phase of the cell 
cycle to another is regulated by different cell cycle checkpoints and in particular by the G1/S 
(transition through the G1 phase to the S phase), the intra S and the G2/M checkpoints 
(transition to the G2 phase and entry in the mitosis). The activation of the G1/S checkpoint is 
mainly regulated through the activity of the tumor-suppressor p53 which have been showed to 
be one of the direct substrate of ATM/ATR activation via the phosphorylation on serine 15 
(ser15). Different sequential phosphorylations, contribute to p53 stabilization and prevent the 
ubiquitination and consequently degradation enhanced by the negative regulator of p53, 
Mdm2[36]. The regulation of p53 in the G1/S checkpoint is also related to the activation of two 
direct substrates of both ATM and ATR, respectively the checkpoint kinase 2 (Chk2) and the 
checkpoint kinase 1 (Chk1), that promote the activatory phosphorylation of p53 on serine 20 
(ser20)[37,38]. Once fully activates, p53 promote the transcription of different genes involved 
in cell cycle regulation, like the CDKN1A (Cyclin-Dependent Kinase Inhibitor 1A (P21, Cip1)), and 
in the induction of apoptosis, like BAX/PUMA/NOXA[39]. The transition through the S phase is 
mainly regulated by a specific phosphate, Cdc25A[40]. This protein is necessary to remove the 
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inhibitory phosphorylation on tyrosine 15 (tyr15) and threonine 14 (thr14) on Cyclin-depend 
kinase 2 (CDK2, Cdc1). During normal replication CDC25A activates CDK2 promoting the 
formation of the complex CDK2-CyclinE/CyclinA necessary for entry into the S phase and for the 
DNA synthesis. In the presence of DNA damages both Chk1 and Chk2 phosphorylate Cdc25A on 
serine 136 (ser136) promoting its ubiquitination by SCF/TrCP ubiquitin ligase complex and 
degraded by proteasome. The inhibition of Cdc25A causes an S phase delay allowing the repair 
of DNA damages before cell cycle progression continues. Similar to the regulation of the S 
phase also the transition from the G2 to the M phase is strictly related to the activation of 
specific phosphates and in particular to the activation of both Cdc25B and Cdc25C. During 
checkpoint activation Cdc25B is phosphorylated at serine 323 (ser323), by Chk1, and bound by 
14-3-3 that blocks its catalytic activity [41,42]. Both Chk1 and Chk2 negatively regulate Cdc25C 
via phosphorylation of a serine reside (ser216), this event create a site for the binding to 14-3-3 
protein resulting in its cytoplasmic sequestration and G2/M checkpoint activation. The events 
that follow Cdc25C sequestration are analogue of the once that follows Cdc25A degradation. 
The segregation of this phosphatase in the cytoplasm prevents its accumulation into the 
nucleus and consequently the inactivation of a protein complex crucial for the transition 
through the G2/M phase, the CDK1 (Cdc2)-CyclinB complex. This complex is finely regulated not 
only by Chk1 or Chk2 but also by two proteins of the Wee1 family, Wee1 and Myt1. While both 
kinases can inhibit CDK1 through the phosphorylation on Tyrosine 15 (Tyr15), Myt1 can also 
phosphorylate on Threonine 14 (thr14), which has been shown to negatively regulate CDK1 as 
well. Thus after the activation of the G2/M checkpoint Chk1, Chk2 and Wee1 cooperate to 
negative regulate the CDK1 to prevent the formation of the complex with the cyclin B[43]. 
[43].Although the regulation of Wee1 during normal cell cycle have been established[44], the 
mechanisms by which Wee1 is activated in response to DNA damages in human is still not fully 
understood[45]. During normal cell division Polo kinase 1(PLK1) phosphorylates Wee1 
promoting its degradation and, consequently, the beginning of the mitosis. After DDR activation 
both ATM and ATR promote the inhibitory phosphorylation of PLK1, leading to the nuclear 
accumulation of Wee1[46].  
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Figure 4: Activation of cell cycle checkpoints. Cell cycle progression is arrested primarily 
through ATM and ATR dependent phosphorylation of p53, Chk1 and Chk2. The G1/S checkpoint 
is primarily mediated through a p53-dependent increase in p21, a cyclin-dependent kinase 
inhibitor. Key targets of Chk1/2 include the Cdc25 phosphatases that control the activity of 
specific cyclin–CDK complexes, which in turn regulate progression through S-phase and the 
G2/M checkpoint. Phosphorylation of Cdc25A/B/C phosphatases by Chk1/2 inhibits their 
activity ensuring that CDK–cyclin complexes are not activated. The inhibition of the 
CDK1/CyclinB complex, crucial for the G2/M transition, is enforced by the activity of Wee1 
kinase. This kinase directly phosphorylates CDK1 keeping this kinase inactive. 
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The consequences of the activation of the DDR system are not limited to the regulation of cell 
cycle progression but are also related to the induction of DNA repair. The major pathways of 
DNA repair are the Homologous Recombination repair (HRR) and the Non-Homologous End 
Joining (NHEJ), which may operate in several variants. The choice between these two 
mechanisms depends on the cell cycle phase. Indeed the NHEJ is a rapid mechanism active 
during all the phases of the cell cycle but in inactive during mitosis where the HRR system 
predominates, due to the presence of sister chromatin as template for the repair of the 
damages[47]. HRR is a slow, high accurate, process which involves many proteins including: the 
MRN complex, RPA, RAD51, RAD52, RAD54, BRCA1, BRCA2 and other proteins. A key protein in 
the HRR is RAD51. Cells deficient for RAD51 accumulate DSBs after replication or at stalled 
replication forks. Chk1 has been found to directly interact with different element of the HRR 
and in particular with RAD51. In response to DNA damages, Chk1 phosphorylates RAD51 on 
threonine 309 (thr309), promoting its recruitment at the site of damage[48]. Also Chk2 
promote the HR system and in particular through the phosphorylation of BRCA2 on threonine 
3387 (thr3387), which is critical for RAD51 localization to DSBs and through the 
phosphorylation of BRCA1 on serine 988 (ser988) [49]. The core machinery for NHEJ is typically 
considered to include the Ku heterodimer (Ku 80/70), the DNA dependent protein kinase 
catalytic subunit (DNA-PKcs), DNA Ligase IV, XRCC4 (X-ray repair cross-complementing protein 
4), and the XRCC4-like factor (XLF, or Cernunnos)[50,51]. This process begins with the binding of 
the KU70/KU80 heterodimer to the DNA ends. This event then recruits DNA-PKcs to form the 
DNA-PK holoenzyme. The DNA ends are resected by the Artemis and/or MRE11/RAD50/NBS1 
(MRN) nucleases, followed by XRCC4/DNA Ligase IV/XLF before the ligation starts by DNA Ligase 
IV[52]. In NHEJ critical is the role of ATM, by protecting the DNA ends from degradation. This 
protection involves a variety of proteins associated with the DSB repair complex, including 
53BP1, histone γH2AX and the MRN complex[53]. 
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Checkpoint kinase inhibitors  
 
Although the checkpoint kinases in normal cells are crucial for the maintenance of genetic 
stability, in cancer development these kinases protect tumor cells from the replication 
stress[54]. In tumor cells the high proliferative rate, induced by oncogenes, or an hypoxic 
microenvironment can induce replication stress and consequently the hyper-activation of the 
ATR/CHK1 in S phase cells[55,56]. On these bases the use of checkpoint kinase inhibitors, even 
in single agent, can drastically mine the mechanisms by which tumor cells sustain the 
replicative stress and thus promote cancer cells death.[57] Moreover, due to the elevated 
proliferation rate oncogene-driven that characterized different types of tumors, the use of 
checkpoint kinase inhibitor could be a promising strategy to selectively target tumor cells and 
to limit off-target toxicity on normal tissue. In addition, due to the central role in the response 
to DNA damages, different checkpoint kinase inhibitors (Chk-i) have been developed to 
specifically inhibit the mechanisms by which tumor cells respond to DNA damaging agents. 
Initially this class of compounds have been developed for the treatment of p53 mutated tumors 
because of their impair functionality of the G1/S checkpoint, and then their applicability have 
been extended also to p53 wild type tumors[58,59]. These compounds have been developed to 
potentiate the efficacy of different chemotherapeutic compound especially for the treatment of 
solid tumors[60]. Indeed the number of publications and clinical trials evaluating the 
effectiveness of this compound in solid tumors is in constantly growth but only few studies 
have been performed for the evaluation of the efficacy of the Chk-Is in hematological 
malignances. The following section summarizes the main studies that have been done to 
evaluate the efficacy of different Chk1/Chk2/Wee1 inhibitors in leukemia (Figure 5). 
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Figure 5: The DDR pathway in cancer cell. The left cartoon shows that the up-regulation of the 
DDR pathway increase the tolerable level of DNA damages and induces chemo-resistance to 
genotoxic agents. The right cartoon shows that the inhibition of the DDR pathway can increase 
the intrinsic genetic instability inducing massive DNA damages. Moreover the inhibition of the 
DDR using different inhibitors sensitizes cells to the toxic effect of chemotherapy. 
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Checkpoint kinase 1 (Chk1)/Checkpoint kinase 2 (Chk2) inhibitors 
 
In the last decade the number of publications evaluating the preclinical and clinical efficacy of 
small molecule inhibitors of Chk1 is constantly growth [61] as well as the number of molecules 
against this kinase[62,63]. The first inhibitor of Chk1 was the UCN-1 (known as staurosporine). 
This molecule have been shown to inhibit not only Chk1 but also other different kinases (Chk2, 
CDK1, CDK2, PKC 7and MK2) and to promote the G2/M checkpoint override upon treatment 
with DNA damaging agents such as cisplatin or topoisomerase inhibitor. UCN-01 was tested in a 
number of clinical trials however the low specificity of the compound caused many harmful 
side-effects and this have not allowed its progression beyond phase II of clinical trials [64,65]. 
 MK-8776 (SCH900776) is a potent and selective Chk1 inhibitor in clinical development. It 
rapidly, less than two hours, induced gH2AX accumulation and suppressed Chk1 functionality 
(shown by the reduction of the auto-phosphorylation site of serine 296). The efficacy of this 
inhibitor was assessed not only in single agent but also in combination with different genotoxic 
compounds showing chemotherapy sensitization by increasing the level of DSBs. Many other 
studies confirmed the great efficacy of this compound for the treatment of different kind of 
tumors and today the MK-8776 entered in phase II clinical trials in combination with 
chemotherapy [62,66–68]. The efficacy of the compound was also evaluated on hematological 
malignances. Day and colleagues[68] demonstrated that MK-8776 synergistically potentiated 
the histone deacetylase (HDAC) inhibitor (HDACI) vorinostat on both AML cell lines and primary 
cells. Moreover they showed that efficacy of the combination was independent on the 
mutational status of p53 and that the synergistic interactions were associated with inhibition of 
Chk1 activity, interference with the intra-S-phase checkpoint, disruption of DNA replication, and 
down-regulation of proteins involved in DNA replication and repair [68]. 
AZD7762 is an ATP competitive Chk1/Chk2 inhibitor. This compound was evaluated in different 
trials as a chemo-sensitizer agent for conventional chemotherapy. It has been described that 
lung cancer cells expressing high levels of Chk1 were hypersensitive to AZD7762. This suggests a 
correlation between Chk1 inhibitor-mediated sensitivity and elevated amounts of Chk1 [89]. 
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Different further studies were conducted to investigate the efficacy of ASD7763 in combination 
with different compound. Indeed it has been reported that combination of AZD7762 with 
gemcitabine and ionizing radiation deeply sensitized pancreatic cells to radiation[69]. The 
efficacy of the compound has been evaluated also in hematologic malignances, e.g in different 
myeloma multiple (MM) cell lines. In the combination studies the researchers showed that 
AZD7762in combination with alkylating agents (melphalan) promoted apoptosis and mitotic 
catastrophe of p53-mutated MM cells[70]. Moreover the Didier et al.[71], showed that 
AZD7762 enhances genotoxic treatment efficacy in immature KG1 leukemic cell line and in AML 
primary leukemic cells. In this study they also correlated the sensitivity to the checkpoint kinase 
inhibitors with patients with a complex karyotype highlighting that this group of patient was 
displays major genomic instability and chemo-resistance [71].  
PF-0477736 is a selective and competitive inhibitor for the Chk1 ATP site. Its specificity is one 
hundred times stronger for Chk1 than for Chk2.The efficacy of this compound have been well 
established against different kinds of tumors. In ovarian cancer it has been showed that tumor 
cells strongly respond to treatment with PF-0477736 but generate metastasis and chemo-
resistant clones [72]. The efficacy of PF-0477736 has been evaluated also in leukemia. 
Sarmento et al. [73] demonstrated that the T-ALL primary samples express higher level of Chk1 
kinase in comparison to normal thymocyte. The treatment with PF-0477736 promoted 
apoptotic cell death, Chk1 inhibition and consequently impaired replication and abrogation of 
G2/M checkpoint in T-ALL cells. Interestingly, this inhibitor in vitro did not significantly affect 
the viability of normal thymocyte cells[73].  
LY2603618, a potent and selective inhibitor of Chk1, is the first second generation checkpoint 
kinase inhibitor that have been evaluated in a clinical trial [74].King and colleagues [75] 
reported that the treatment with LY2603618 produced a cellular phenotype similar to that 
reported for depletion of Chk1 by RNAi. Moreover they reported that the inhibition of Chk1 
caused impaired DNA synthesis, elevated H2A.X phosphorylation and premature entry into 
mitosis. Finally they showed that LY2603618 was able to override the G2/M checkpoint 
activated after the exposure to doxorubicin, resulting in cells entering into metaphase with 
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poorly condensed chromosomes[75].It has been reported that LY2603618 potentiated the 
effect of different DNA damage drugs like pemetrexed and cisplatin in vitro. This result was 
confirmed in vivo using a tumor xenograft approaches and were the bases for a phase I clinical 
trials evaluating the effectiveness of LY2603618 in combination with pemetrexed and cisplatin 
in patients with advanced cancer [74]. 
LY2606368 is a novel Chk1/Chk2 inhibitor which has been reported to causes as a single agent 
DBSs while simultaneously removing the protection of the DNA damage checkpoints. King and 
colleagues reported that LY2606368 increases extensive DNA damage in the S phase cell 
population highlighting the possible mechanism of death through replication catastrophe[76].  
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Wee1 inhibitors 
 
Many Wee1 inhibitors have been developed to override checkpoint signaling and, 
consequently, to improve the sensitivity of tumor cells to the toxic effect of different genotoxic 
agents. Several studies have shown their efficacy in the treatment of different kinds of tumors 
not only in combinatorial studies but also as single agent. The PD0166285 is a non-selective 
kinase inhibitors, which targets Wee1 but also Chk1, Myt1, c-Src, PDGFR-, fibroblast growth 
factor receptor-1, and epidermal growth factor receptor tyrosine kinases [77,78]. This inhibitor 
has been shown to successfully inhibit CDK1 phosphorylation (tyrosine 15 and threonine 14) 
and to abrogate G2/M checkpoint after IR irradiation in vitro (Figure 6).  
MK-1775 (AZD1775) is currently mostly studied Wee 1 inhibitor. Several studies have shown 
that this particular inhibitor selectively sensitizes p53-deficient cancer cells to the toxic effect of 
gemcitabine, carboplatin, 5-fluorouracil and cisplatin [79–82]. The sensitizing activity of MK-
1775 selectively on p53 deficient cells has been showed also after irradiation. Although all the 
above mentioned studies, recent finding highlighted that the effectiveness of this compound in 
different types of tumor is independent by the functional status of the tumor-suppressor p53 
[83]. Today several studies on hematological malignancies, mostly on acute myeloid leukemia, 
have showed the efficacy of this compound, not only as single agent [84] but also in 
combination with different compound like HDAC ( e.g., vorinostat) [85,86] or like cytarabine 
(AraC). Finally, different studies showed the synergistic efficacy between Chk1 and Wee1 
inhibitors on different tumor cell lines and on primary cells [87–89].Today the efficacy of MK-
1775, either as a single agent or in combination with different DNA-damaging agents, is 
currently evaluated in different clinical trials (https://clinicaltrials.gov). The first study 
conducted on patients with refractory solid tumors evaluating the maximum-tolerated dose 
(MTD), the pharmacokinetics, and the modulation of phosphorylated forms of CDKs and of 
histone H2AX (γH2AX) in paired tumor biopsies showed that, in line with the per-clinical 
studies, MK-1775 decreased CDK1 phosphorylation (tyrosine 15) and increased H2AX 
phosphorylation[90]. 
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Figure 6: Schematic representation of the role of Wee1 in the activation of the G2/M 
checkpoint and the consequence of its inhibition using Wee1 inhibitors. 
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Aims  
  
27 
 
  
The overall aim of this study was to evaluate the efficacy of different checkpoint kinase 
inhibitors for the treatment of ALL as single agent or in combination with various compounds 
normally used in the clinic for the treatment of ALL patients.  
The specific aims were the followings: 
1. Different elements of the DNA damages response pathways are up-regulated in many 
tumors. Indeed, the activation of different oncogenes frequently causes replicative stress and 
tumor cells, in order to sustain the high replicative stress, up-regulate different elements of the 
DDR. Different studies have shown that the up-regulation of these keys elements of the DDR is 
fundamental to sustain the high genetic instability. Starting from this background the first aim 
was to evaluate the efficacy of a Chk1/2 inhibitor, PF-0477736, as single agent on a panel of 
different B-/T-ALL cell lines, on primary leukemic cells isolated from peripheral blood and bone 
marrow of adult ALL patients, and on a mouse model. 
2. Different checkpoint kinase inhibitors have been developed to specifically sensitize 
tumor cells to the cytotoxicity of genotoxic agents. The second aim of the study was to evaluate 
the chemo-sensitizer efficacy of LY2606368, a selective Chk1/Chk2 inhibitor, on leukemic cell 
lines and primary cells. The efficacy of LY2606368 was firstly evaluated as single agent and then 
in combination with different compounds like tyrosine kinase inhibitors, imatinib or dasatinib, 
and the purine nucleoside analogue clofarabine.  
3. The final aim of this study was to evaluate the effect of the inhibition of WEE1 kinase, 
using MK-1775 inhibitor, as single agent and in combination with different compounds like 
tyrosine kinase inhibitors (two isomer of bosutinib), purine nucleoside analogue (clofarabine), 
and Chk1/Chk2 inhibitor (PF-00477736) on B-/T-ALL cell lines and on primary leukemic cells 
isolated from adult B-ALL patients. 
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Abstract 
Background: Although progress in children, in adults ALL still carries a dismal outcome. Here, we 
explored the in vitro and in vivo activity of PF-00477736 (Pfizer), a potent, selective ATP-
competitive small-molecule inhibitor of checkpoint kinase 1 (Chk1) and with lower efficacy of 
checkpoint kinase 2 (Chk2). Methods: The effectiveness of PF-00477736 as single agent in B-/T-
ALL was evaluated in vitro and in vivo studies, as single agent The efficacy of the compound in 
term of cytotoxicity, induction of apoptosis, changes in gene and protein expression was 
assessed using different B-/T-ALL cell lines. Finally the action of PF-00477736 was assessed in 
vivo using leukemic mouse generated by a single administration of the tumorigenic agent N-
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ethyl-N-nitrosourea. Results: Chk1 and Chk2 are over expressed concomitant with the presence 
of genetic damage as suggested by the nuclear labeling for γ-H2A.X (Ser139) in 68% of ALL 
patients. In human B- and T- ALL cell lines inhibition of Chk1/2 as a single treatment strategy 
efficiently triggered the Chk1-Cdc25-Cdc2 pathway resulting in a dose and time-dependent 
cytotoxicity, induction of apoptosis and increased DNA damage. Moreover, treatment with PF-
00477736 showed efficacy ex-vivo in primary leukemic blasts separated from 14 adult ALL 
patients and in vivo in mice transplanted with T-ALL, arguing in favor of its future clinical 
evaluation in leukemia. Conclusions: In vitro, ex-vivo and in vivo results support the inhibition of 
Chk1 as a new therapeutic strategy in acute lymphoblastic leukemia and they provide a strong 
rationale for its future clinical investigation. 
 
Background 
Acute lymphoblastic leukemia represents a biologically and clinically heterogeneous group of 
B/T-precursor-stage lymphoid cell malignancies arising from genetic insults that block lymphoid 
differentiation and drive aberrant cell proliferation and survival. Survival rates for children are 
approximately 80%-85% with current risk-oriented treatment protocols in contrast to less than 
40% for adults[91–93]. Although the outcome of children with relapsed ALL is heterogeneous, 
many achieve lasting second remissions. In contrast, survival after relapse in adult ALL is 
short[94,95]. New therapeutic strategies are therefore needed to improve remission rates in 
adults and to prevent relapse both in adult and pediatric ALL patients. 
Recently, in order to enhance DNA-damaging effects inflicted by cytotoxic drugs or radiation, 
different checkpoint kinase (Chk) inhibitors have been developed and assessed alone or in 
combination with DNA damaging agents in preclinical studies and in PhaseI/II trials for cancer 
therapy[96–104]. Some of them inhibit both Chk1 and Chk2, other have a higher specificity for 
Chk1. The biological background underlying the development of Chk1 inhibitors and preliminary 
data deriving from early clinical trials have been recently well reviewed in[105]. Following DNA 
damage multiprotein complexes recruit the transducers ataxia telangiectasia mutated (ATM) 
and ataxia telangiectasia and Rad3-related protein (ATR) which activate Chk2 and Chk1, 
respectively, despite an existing extensive crosstalk between the ATR-Chk1 and ATM-Chk2 
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pathways. Once activated by phosphorylation at S317/S345 in response to DNA single strand 
breaks, Chk1 phosphorylates the phosphatase Cdc25A at the G1/S and S phase checkpoints 
preventing cells from entering S phase and Cdc25A and Cdc25C at the G2/M checkpoint 
avoiding the entry in mitosis[106–109]. If Chk1 is induced by single strand breaks, Chk2 
activation is largely restricted to DNA double strand breaks via ATM[38]. Once activated, they 
mediate cell cycle delay, DNA repair, and apoptosis in response to DNA damage. Moreover, 
Chk1 is required for proper mitotic spindle assembly and maintenance of chromosomal stability 
during mitosis[110].  
PF-00477736 is a potent, selective ATP-competitive small-molecule inhibitor of Chk1, 
synthesized by Pfizer, which is selective for Chk1 and shows general selectivity over other 
kinases[96]. Preclinically, PF-00477736 enhanced docetaxel activity in tumor cells and 
xenografts by abrogating the mitotic spindle checkpoint, as well as the DNA damage 
checkpoint[100]. The checkpoint abrogating activity and cytotoxic activity attributed to PF-
00477736 in combination with chemotherapy agents (e.g gemcitabine and carboplatin) showed 
selectivity for p53-defective cancer cell lines over p53-competent normal cells in vitro[96] . In 
xenografts, PF-00477736 enhanced the antitumor activity of gemcitabine in a dose-dependent 
manner. PF-00477736 combinations were well tolerated with no exacerbation of side effects 
commonly associated with cytotoxic agents[96].  
In this study, we investigated the activity of PF-0477736, as a single agent in B-/T-ALL by: 
assessment of the in vitro efficacy in ALL cell lines and primary blast cells; assessment of the in 
vivo efficacy in mouse models; identification and validation of potential biomarkers of 
functional inhibition. Results demonstrated that in vitro treatment of B-/T-ALL cell lines and 
primary blast cells with PF-0477736 resulted in inhibition of cell viability, induction of DNA 
damage and apoptosis. Moreover, in vivo studies confirmed the efficacy of Chk1 inhibition, 
suggesting that this therapeutic strategy may be promising in leukemia.  
 
Results 
Chk1 and Chk2 are overexpressed in acute lymphoblastic leukemia 
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Chk1/2 transcript levels were assessed by qPCR in eight cell lines from B/T- ALL (BV-173, SUP-
B15, REH, NALM-6, NALM-19, MOLT-4, RPMI-8402 and CCRF-CEM)(Fig. S1) and in blast cells 
from 54 adult newly-diagnosed ALL cases including 41 (76%) BCR-ABL1-positive and 13 (23%) 
BCR-ABL1-negative cases. Normal bone marrow precursor cells isolated from leukemia patients 
in complete remission were also analyzed by the same method. In this cohort higher transcript 
levels of Chk1 but not Chk2 were found in leukemia cell lines and newly diagnosed ALL cases 
compared to normal bone marrow mononuclear cells (p value < 0.001) (Fig. 1). The web-based 
public database Oncomine[111] (https://www.oncomine.org/) was queried for Chk1/2 
expression in the available leukemia datasets based on the comparison leukemia versus normal 
using a criterion of a 2 fold change for both Chk1 and Chk2 expression and a p-value of 1E-4. 
Using these stringent criteria, we found that both Chk1 and Chk2 transcripts are highly 
overexpressed in B-ALL and T-ALL if compared to normal bone marrow samples (Fig. 2S). We 
then investigated by immunohistochemistry formalin-fixed paraffin-embedded (FFPE) tissue 
samples collected at diagnosis from 60 ALL patients (36 B-ALL and 24 T-ALL) for protein 
expression of Chk1, phosphorylated Chk1 (Ser345), Chk2, phosphorylated Chk2 (Thr68), 
Cdc25C, phosphorylated Cdc25C (Ser 2016)  and phosphorylated H2A.X (Ser139) (γ-H2A.X). 
Results are detailed in Table 1 and viewed in Fig. 1C. Among B/T-ALL, a diffuse positivity for 
Chk1, Chk2, CDdc25c and the phosphorylated forms of Chk1 (Ser345) and CDCdc25c (Ser216) 
was observed; these were detected in 51/54 (96%), 55/57 (94%), 57/57 (100%), 45/56 (80%) 
and 38/55 (70%) of the cases respectively, whereas 15/55 (27%) of ALLs stained for 
phosphorylated form of Chk2 (Thr68) (Fig. 1D). Interestingly, in our ALL series, genomic damage 
was suggested by the nuclear labeling for γ-H2A.X molecule in 40/59 (68%) of samples (Fig. 1D). 
In thymuses, normal lymphoblasts did not show protein expression of Chk1, Chk2, Cdc25C and 
their phosphorylated counterparts (Fig. 1D). In B follicles of the reactive lymph node, in spite of 
the Chk1 weak positivity, diffuse Chk2 and Cdc25C nuclear staining, no phosphorylation in their 
amino acid Ser345, Thr68 and Ser216 respectively, was detected (Fig. 1D). Notably, in thymuses 
and reactive B follicles, only scattered γ-H2A.X+ cells were present, indicating a low level of 
genomic damage in physiologic conditions compared to ALLs (Fig. 1D). 
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Figure 1. Chk1 (A) and Chk2 (B) mRNA expression levels in leukemia cell lines (BV-173, SUP-B15, 
REH, NALM-6, NALM-19, MOLT-4, RPMI-8402 and CCRF-CEM), blast cells from fifty-four adult 
newly-diagnosed ALL cases and in normal bone marrow mononuclear cells (MNC). Results are 
expressed as Log10 2exp[-(ΔΔCt)] and they are the mean of at least two different replicates. C. 
Immunohistochemical profile of the 60 ALL (36 B-ALL and 24 T-ALL); a red box indicates 
expression of the marker, whereas a green box signifies negativity (samples were considered 
positive if 30% or more of the cells were stained with an antibody); gray box indicates a not 
evaluable reaction due to a core loss in TMA.  The figure allows the assessment of the co-
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expression of the DNA damage markers in individual samples D. Immunohistochemical 
expression of Chk1, phosphorylated Chk1 (Ser345), Chk2, phosphorylated Chk2 (Thr68) and 
phosphorylated H2A.X (Ser139) (γ-H2A.X) in thymus, reactive follicle (RF), T-ALL and B-ALL.  The 
figure highlights the close similarity between expression profiling of B- and T-ALL, characterized 
by a high percentage of cases Chk1+, pChk1+, Chk2+ , Cdc25C, pCdc25C, pH2A.X+ and,  in a lesser 
extent , pChk2+, and its distinction with the expression profiling of the non tumoral populations 
as maturing thymocytes, that were substantially negative for these seven proteins and as B 
lymphocytes of reactive follicles, that resulted Chk1 weakly  +, Chk2+, Cdc25C+ but  negative for 
the corresponding phosphorylated forms and  pH2A.X. a) thymus: thymocytes Chk1-  (x400); b) 
RF: B lymphocytes in mantle zone (MZ) and germinal center (GC) showing weak Chk1 positivity 
(x100); c) strong expression of Chk1 in T-ALL and d) B-ALL (x400). e) thymus: thymocytes pChk1-  
(x400); f) RF: B lymphocytes in MZ and GC  pChk1-; g) strong positivity of pChk1 in T-ALL and h) 
B-ALL (x400);  i) thymus: normal lymphoblasts  Chk2-  (x400); j) RF: B lymphocytes in MZ and GC 
showing diffuse Chk2 positivity (x100); k) strong nuclear staining  for Chk2 in T-ALL and l) B-ALL 
(x400). m) thymus: thymocytes pChk2-  (x400); n) RF: B lymphocytes in MZ and GC  pChk2- 
(x100); o) diffuse expression of  pChk2 in T-ALL and p) B-ALL (x400);  q) thymus: normal 
lymphoblasts negative for Cdc25C (x400); r) RF: B lymphocytes in mantle zone (MZ) and 
germinal center (GC) showing weak Cdc25C positivity (x100); s) strong nuclear staining  for 
Cdc25C in T-ALL and t) B-ALL (x400); u) thymus: thymocytes pCdc25C-  (x400); v) RF: B 
lymphocytes in MZ and GC  pCdc25C- (x100); w) diffuse expression of  pCdc25C in T-ALL and x) 
B-ALL (x400);  y) thymus: normal lymphoblasts negative for pH2A.X (γ-H2A.X) (x400); z) RF: MZ 
B and GC lymphocytes substantially pH2A.X (γ-H2A.X) negative,  with only occasional GC 
positive cells (x100); aa) strong nuclear staining  for pH2A.X (γ-H2A.X)  in T-ALL and ab) B-ALL 
(x400). 
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PF-00477736 reduces cell viability in a dose-dependent manner 
B-/T-ALL cell lines were incubated with increasing concentrations of drug (5-1000 nM) for 24 
and 48 hours. PF-00477736 inhibition resulted in dose and time-dependent cytotoxicity with 
RPMI-8402 (T-ALL) being the most sensitive (IC50 = 57.4 nM at 24 hours), while NALM-6 (B-ALL) 
the most resistant (IC50 = 1423.0 nM at 24 hours). In vitro sensitivity does not correlate with 
leukemia cell type (B-ALL vs T-ALL), TP53 mutation status (BV-173, SUPB-15, NALM-6 and 
NALM-19 cells were p53 wild-type whereas REH, MOLT-4, RPMI-8402 and CEM cells were p53 
mutated) (Fig. 2A) and with baseline levels of Chk1/2 and ATR/ATM phosphorylation, indicative 
of intrinsic genetic stress (Fig. 2B). 
PF-00477736 induces apoptosis at 24 and 48 hours in B-/T-ALL cells 
In order to assess whether cytotoxicity was correlated to increased susceptibility to apoptosis, 
B-/T-ALL cell lines were incubated with increasing concentrations of drug (0.1, 0.5 and 1 μM and 
0.05, 0.1 and 0.2 μM only for BV-173 and RPMI-8402) for 24 and 48 hours. Consistent with the 
viability results, Annexin V/PI staining analysis showed a significant increase of apoptosis at 24 
and 48 hours in B- and T-ALL cells proportional to drug-dose and drug-exposure time (Fig. 3S-A). 
The induction of apoptosis by PF-00477736 was also assessed by detection of poly (ADP-ribose) 
polymerase (PARP) cleavage by Western blot analysis[112]. The PARP-1 cleavage band at 89 
kDa was observed in lysates from leukemia cell lines after 24 hours of drug exposure, while it 
was undetectable in cells treated with only DMSO 0.1% (Fig. 2C). 
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Figure 2. A. IC50 values for B- and T-ALL cell lines at exposure durations of 24 and 48 hours (hrs) 
to PF-0477736. For each cell line the mutational status of TP53 gene is shown. Abbreviations: 
WT, wild-type; hrs: hours. B. Assessment of the expression and activation of the major 
components of the ATR-Chk1 and ATM-Chk2 pathways in B-/T-ALL cell lines at baseline. The 
homogeneity of the protein loaded was determined by using as an internal control (β-actin). C. 
Reduction of PARP-1 cleavage in leukemia cell lines detected by western blotting. PARP-1 
cleavage was detected as a marker of apoptosis. Β-actin was detected on the same membrane 
for loading normalization.  
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PF-00477736 perturbs the cell cycle profile in B-/T-ALL cells 
The effect of the inhibition of Chk1 pathway on cell cycle progression was evaluated in RPMI-
8402, BV-173, SUP-B15 and NALM-6 cell lines. Cells were incubated with increasing 
concentration of PF-00477736 for 6 and 24 hours and then stained with propidium iodide to 
quantify the DNA amount. The effect of PF-00477736 on the cell cycle progression was very 
weak after 6 hours of incubation (data not showed) and very heterogeneous among the 
different cell lines after 24 hours. In RPMI-8402, BV-173 and SUP-B15 cell lines the treatment 
induced a progressive reduction of the number of cells in S and G2/M phase and a concomitant 
increment of cell debris. In the less sensitive cell line, NALM-6, the inhibition of Chk1 
progressively increased the percentage of cells in G2/M phase and reduced the percentage of 
cells in G1 phase (Fig. 3S-B). 
PF-00477736 efficiently targets Chk1 pathway and induces DNA damage 
In order to assess whether PF-00477736 efficiently targeted Chk1 pathway, we examined the 
changes in the downstream phosphorylation of the phosphatase Cdc25C and cyclin-dependent 
kinase, Cdc2. Moreover, Chk1 itself and γ-H2A.X, which is a marker of stalling replication forks 
and checkpoint abrogation-induced apoptosis, have been assessed. Functional analyses were 
initially performed on the most sensitive (BV-173) and the most resistant (NALM-6) B-ALL cell 
lines, as determined by the viability and apoptosis analyses. Specifically, BV-173 cells were 
treated with 0.05, 0.1 and 0.2 μM and NALM-6 with 0.1, 0.5 and 1 μM of PF-00477736 for 24 
hours (Fig. 3A). In the second analysis BV-173 and NALM-6 cells were treated with the dose of 
PF-00477736 that goes near to the IC50 (0.1 μM for BV-173 and 1 μM for NALM-6) for 18, 24, 30 
and 48 hours (Fig. 3B). Thereafter, the same molecular targets have been assessed on all B- and 
T-ALL cell lines using the dose that goes near to the IC50 (Fig. 4S). Active Chk1 phosphorylates 
Cdc25C at serine 216 throughout interphase and upon G2 checkpoint activation. This leads to 
the nuclear export of Cdc25C and its subsequent cytoplasmic sequestration by 14-3-3 protein, 
which prevents the activation of the downstream target of Cdc25C, the cyclin B/Cdc2 kinase 
that is responsible for G2/M transition[113]. Upon inhibition of Chk1, we observed decreased 
levels of phosphorylated Cdc25c (Ser 216) and Cdc2 (Tyr 15) as well as reduced levels of their 
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total forms in a dose and time-dependent manner, suggesting that PF-00477736 efficiently 
targets Chk1 pathway. In contrast, the phosphorylated forms of Chk1 (Ser317 and Ser345) were 
dose-dependently increased suggesting that treatment amplifies genomic damage which in a 
feedback loop increases Chk1 phosphorylation. Although the increment of the phosphorylated 
forms of Chk1 (ser317 and ser345) as a consequence of genomic damage amplification, the 
complete inhibition of Chk1 functionality was confirmed by the progressive reduction of the 
auto-phosphorylated form of Chk1 (ser296) in a early time point analysis. Indeed even after 3 
hours of treatment with PF-00477736 in both BV-173 and NALM-6 cell lines the auto-
phosphorylated form of Chk1 (ser296) was drastically reduced in comparison with the 
untreated counterpart (Fig. 4S-B).The enhancement of genomic damage was also confirmed by 
the time-dependently increase of γ-H2A.X both in western blot and immunofluorescence 
analysis. The phospho-H2A.X accumulates and forms characteristic nuclear foci where the DNA 
is damaged [114] . Both NALM-6 and BV-173 cell lines show an increased number of γ-H2A.X 
foci when treated with PF-00477736 compared to untreated controls (Fig. 3C). However, 
evaluating the mean fluorescence intensity of γ-H2A.X positive cells, BV-173 cells seem to be 
more damaged than NALM-6. Actually, BV-173 treated cells have 5-fold change difference of 
mean value intensity of γ-H2A.X compared to BV-173 untreated cells, while NALM-6 treated 
cells have 1.4-fold change difference of mean value intensity of γ-H2A.X compared to their 
untreated counterparts. In addition to these changes in the overall amount of γ-H2A.X foci 
among the two different cell types we observed the presence of hyper-γ-H2A.X-positive cells 
specifically in BV-173 cells treated with PF-00477736. The so called hyper-γ-H2A.X-positive cells 
loose the typical foci signal of γ-H2A.X and emit a much higher and diffuse signal of γ-H2A.X 
positivity. Almost 6.5% of the γ-H2A.X-positive cells are hyper-γ-H2A.X-positive in BV-176 
treated cells compared to 1.8% in the untreated controls. These data suggest a higher induction 
of DNA damage upon PF-00477736 treatment in BV-173 than NALM-6 cells as expected by the 
fact that BV-173 cells are more responsive to PF-00477736. However, the increase of hyper-γ-
H2A.X-positive cells only in BV-176 treated cells would suggest the existence of a specific effect 
that causes a hyper DNA damage only in a restricted, but significant, population of leukemic 
cells. Interestingly, upon treatment we observed a strong reduction of Chk1. As already 
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hypothesized this may be the result of cleavage by caspase during apoptosis induced by 
genotoxic stress[70,115]. Persisting protein levels of Cdc25, pChk1 ser345, pCdc2 (tyr15) and 
Cdc2 after 48 hours of exposure to PF-00477736 differentiated less sensitive leukemia cells 
from more sensitive ones(Fig. 3C).  
 
Figure 3. A. Western Blot analysis in BV-173 and NALM-6 cell lines after exposure to increasing 
concentrations of PF-00477736 (0.05, 0.1 and 0.2 uM for BV-173 and 0.1, 0.5 and 1uM for 
NALM-6) or DMSO 0.1% (-). B.. Western Blot analysis in BV-173 and NALM-6 cell lines after 
exposure to PF-00477736 (+) at the concentration closest the IC50 or DMSO 0.1% (-) at 18, 24, 
30 and 48 hours. C. Western Blot analysis in all leukemia cell lines after exposure to PF-
00477736 (+) at the concentration closest the IC50 or DMSO 0.1%. 
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Gene expression profiling results 
In order to identify gene expression changes specifically correlated with Chk1 inhibition and to 
better elucidate the mechanism of action of Chk1 inhibitor, GEP analysis was performed by 
microarray on treated B/T ALL cell lines (BV-173, SUP-B15, REH, NALM-6, NALM-19, MOLT-4, 
RPMI8402 and CCRF-CEM) and on their untreated counterparts (DMSO 0.1%) after 24 hours of 
drug exposure. Treatment resulted in a differential expression of 941 genes (p < 0.05): 528 
(56%) were down-modulated and 413 (44%) were up-regulated in treated leukemia cells 
compared to untreated cells (Supplementary Material 1S and Fig. 4). To identify peculiar critical 
pathways affected by Chk1 inhibition, the differentially expressed genes were analyzed in terms 
of biological function using the Metacore pathway-mapping software (GeneGo Inc) which 
categorizes genes in pathway maps, Gene Ontology (GO) cellular processes and cellular and 
molecular process networks. Consistent with a Chk1 mechanism of action, the three top scored 
maps (map with the lowest p value) were “Cell cycle: estrogen receptor 1 (ESR1) regulation of 
G1/S transition” including c-Jun/c-Fos, Cyclin A, CARM1, Skp2/TrCP/FBXW, SKP2, c-Fos, CDK4, 
NCOA3, c-Jun, CDK2 genes (Fig. 5S); “Apoptosis and survival: Granzyme A signaling” including 
PHAP1, Ku70/80, Ku80, Ku70, Histone H3, NDPK A, SET, Histone H2B, Histone H1 genes (Fig. 6S) 
and “DNA damage: ATM/ATR regulation of G1/S checkpoint” including PCNA, growth arrest and 
DNA damage 45 alpha (GADD45a), Chk2, Cyclin A, NF-kB, Cyclin-dependent kinase 4 (CDK4), 
FANCD2, Claspin, CDK2 genes (Fig. 7S). GO cellular processes highlighted 617 genes involved in 
cellular metabolic process (Supplementary Material 2S). Finally, the three top scored process 
networks impaired by the treatment with Chk1 inhibitor were: the DNA damage checkpoint, 
the S phase of cell cycle and the apoptosis, confirming the specificity of treatment on its target 
pathways (Supplementary Material 3S). Thirty-five genes had a false discovery rate less than 
0.05 (Table 1S) and the three most differentially expressed genes were: DNA damage-inducible 
transcript 3 (DDIT3, fold-change 3.32, p-value 6.06E-05), Kruppel-like factor 6 (KLF6, fold-
change 2.17, p-value 8.41E-05) and FBJ murine osteosarcoma viral oncogene homolog (FOS, 
fold-change 2.40, p-value 1.97E-04). Due to its implication in the regulation of the cell cycle and 
apoptosis, western blot analysis against c-jun was performed to better comprehend its 
biological role in response to PF-00477736. C-jun is a component of the transcription factor 
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activating protein-1 (AP-1) which is involved in cell cycle progression through the G1 phase by 
the regulation of the cyclin D1[116]. As soon after treatment with Chk inhibitor c-jun protein 
levels increased in all B-ALL cell lines but not in all T-ALL cell lines in which the response to the 
treatment was very heterogeneous (Fig. 8S-A). The data found in the gene  expression profile 
analysis were validated using qPCR. Four genes (two up-regulated,PLK3 and Gadd45a; two 
down-regulated, Chk2 and CDK4), that have been chosen on their biological relevance in the 
Chk1 pathway, were validates on B-/T-ALL cell lines treated for 24 hours with  or without PF-
00477736 (IC50) (Fig.8S-C). 
 
Figure 4. Heatmap of differentially expressed genes. Lists of differentially expressed genes with 
a t-test P-value < 0.05 were generated for each cell line. A hierarchical clustering method in 
Partek Genomics Suite was used to construct both the gene tree and the sample tree. Data are 
shown in a matrix format: each raw represents a single gene, and each column represents a cell 
line. Red indicates overexpressed genes and blue indicates underexpressed genes (see legend).  
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PF-00477736 reduces viability in primary ALL blast cells 
The efficacy of PF-00477736 was confirmed in primary blast cells from 14 newly diagnosed 
cases including 10 BCR-ABL1-positive (71%) cases and 4 BCR-ABL1-negative ALL cases (29%). 
Leukemic cells were incubated with increasing concentrations of drug (0.1, 0.5 and 1 μM) for 24 
hours. Based on the viability results, three groups of patients were identified: very good 
responders, 36% (5/14) with IC50 at 24 hours ranging from 0.1 and 0.5 μM; good responders, 
43% (6/14) with IC50 at 24 hours ranging from 0.5 and 1 μM; poor responders, 21% (3/14) with 
IC50 at 24 hours higher than 1 μM (Table 2S and Fig. 5A). PF-00477736 did not reduce viability in 
primary cultures of normal bone marrow mononuclear cells, demonstrating that it selectively 
targets leukemia cells (Fig. 5B). Moreover, in contrast to leukemia cells, treatment did not 
induce protein phosphorylation changes in Chk1 (Ser 345), Cdc25c (Ser 216) and Cdc2 (Tyr 15) 
neither increased levels of phospho-H2A.X (Fig.8S-B). 
 
 
PF-00477736 impairs survival of leukemic mice 
We extended the in vitro and ex-vivo studies by assessing the efficacy of Chk inhibitor in mice 
transplanted with T-ALL.  
Leukemic mice were generated by the usage of the tumorigenic agent ENU. The obtained 
leukemia has been immunophenotyped and characterized as a T-ALL. Leukemic blasts coming 
from the spleen of leukemic animals were transplanted into C57BL/6Ly5.1 recipient mice. Three 
days after transplantation, a time sufficient for leukemic blasts to home the bone marrow of 
the host, we started to treat the animals. A concentration of 40mg/kg of PF-00477736 given 
with a q3dx4 schedule seems not to be toxic for the animals, however it significantly affects the 
overall survival of the treated animals (5 mice) in comparison to the untreated ones (7 mice) (p-
value=0.0009). Actually control animals (intraperitoneally injected with PBS) die all at day 17 
post-transplantation while the animals treated with PF-00477736 live longer (up to 59 days 
post transplantation). The leukemia used for the experiments shown here was very aggressive 
43 
 
(untreated animals die with massive infiltration of the spleen and the liver by leukemic blasts at 
day 17) suggesting a reason why the effect of the Chk inhibitor is significant though quite 
variable among treated mice (Fig. 5C). 
 
Figure 5. A. Cell viability results in primary ALL blast cells after 24 hours of exposure to PF-
0477736 at 100, 500 and 1000 nM. B. Cell viability results in normal bone marrow mononuclear 
cells after 24 hours of exposure to PF-0477736 at 100, 500 and 1000 nM. C Survival curves of 
leukemic mice treated with PF-0477736 and control mice injected with vehicle. PF-0477736 
treatment significantly increases the overall survival of mice transplanted with murine lymphoid 
leukemia (p-value = 0.0009). 
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Discussion 
Several studies in different tumors have investigated the role of Chk inhibition in combination 
with conventional chemotherapy demonstrating that this combination enhances tumor cell 
death [6, 10] 
Here, we evaluated the in vitro and in vivo effects of the administration of PF- 00477736 as a 
single agent and not in combination with other chemotherapeutic agents in cell lines and 
primary blast cells from of acute lymphoblastic leukemia based on the hypothesis that the 
intrinsic genomic instability of leukemic clones as demonstrated by the nuclear labeling for γ-
H2A.X molecule in 68% of ALL patients may be itself sufficient to bring the cells to apoptosis. 
According to this hypothesis, it was possible to highlight how the administration of PF- 0477736 
as single agent was able to reduce cell viability in all leukemia cell lines treated in this study (BV 
-173, SUP- B15 , REH , NALM -6 , NALM -19 , MOLT -4, RPMI8402 and CCRF -CEM ) and to induce 
apoptosis (Fig. 6). Different leukemia cell lines showed different sensitivity to PF-00477736 with 
RPMI-8402 (T-ALL) being the most sensitive (IC50 = 57.4 at 24 hours), while NALM-6 (B-ALL) the 
less sensitive (IC50 = 1,423.0 at 24 hours) cell line. Interestingly, the sensitivity to Chk1 inhibitor 
was not related to the mutational status of the tumor suppressor p53.  
The results obtained on cell viability and induction of apoptosis have been confirmed by 
genome-wide studies evaluating global gene expression changes upon treatment and by 
functional studies performed by western blot analysis. Interestingly, by GEP analysis the 
majority of genes down-regulated were involved in the DNA damages response and in 
particular in DNA repair mechanisms, while the genes up-regulated were involved in chromatin 
assembly, nucleosome organization, DNA packaging and apoptosis. The efficacy of Chk 
inhibition has been evaluated and confirmed in term of reduction of cell viability in primary ALL 
blast cells but not in normal bone marrow precursor cells. Furthermore, assessing the efficacy 
of Chk inhibition in mice transplanted with T-lymphoid leukemia, we demonstrated that PF-
0477736 increases the survival of treated mice compared with mice treated with vehicle (p = 
0.0016).  
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In conclusion, in vitro, ex-vivo and in vivo results support the inhibition of Chk1 as a new 
therapeutic strategy in acute lymphoblastic leukemia and they provide a strong rationale for its 
future clinical investigation. The checkpoint kinase inhibitor have been synthetized to increase 
the effectiveness of conventional chemotherapy, preventing cells to arrest cell cycle and to 
repair the DNA damages caused by the exposure to genotoxic agents. Here we highlight that 
even the treatment with a checkpoint kinase inhibitor alone associated with the high genetic 
instability, can be enough to kill cancer cells. Indeed we believe that leukemic cells, thanks to a 
higher activation of the ATR-Chk1/ATM-Chk2 pathways, can better tolerate the high genetic 
instability. Switching off these mechanisms of survive we can kill leukemic cell by overcoming 
the cell cycle checkpoint, by inhibiting the mechanisms of DNA damages repair and by inducing 
massive damages that cannot be tolerate (Fig. 6). 
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Figure 6. Cartoon drawing the rational of the study: in leukemia cells oncogenes could lead to 
replication stress, activation of ATR/Chk1 pathway that in conjunction with elevated 
proliferation promote tolerable level of DNA damage, genomic instability and tumor 
progression. Inhibition of Chk1/Chk2 could increase DNA damage leading to apoptosis 
 
 
Conclusions 
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Inhibition of Chk1/2 represents a novel therapeutic strategy to overcome genetic instability and 
to promote selective killing of leukemia cells in ALL.  
Methods  
Leukemia cell lines  
Human B- (BV-173, SUP-B15, REH, NALM-6, NALM-19),T-ALL (MOLT-4, RPMI-8402, CCRF-CEM) 
cell lines were obtained from Leibniz-Institut DSMZ-Deutsche Sammlung von Mikroorganismen 
und Zellkulturen GmbH (Germany). Cells were cultured in RPMI-1640 medium (Invitrogen, 
Paisley, UK) with 1% l-glutamine (Sigma, St. Louis, MO), penicillin and streptomycin (Gibco, 
Paisley, UK) supplemented with 10%-20% fetal bovine serum (Gibco) in a humidified 
atmosphere of 5% CO2 at 37°C. Online databases have been interrogated to molecularly 
characterize leukemia cell lines: International Agency for Research on Cancer (IARC) TP53 
database (http://www-p53.iarc.fr/) and the Catalogue of Somatic Mutations in Cancer, 
(COSMIC, http:// http://www.sanger.ac.uk/genetics/CGP/cosmic/). The Chk1 inhibitor PF-
00477736 was purchased by Sigma-Aldrich (Sigma-Aldrich Co. St. Louis, Missouri 63103 United 
States).  
Reagents 
The Chk inhibitor PF-00477736 was purchased by Sigma-Aldrich (Sigma-Aldrich Co. St. Louis, 
Missouri 63103 United States).  qPCR analysis Chk1 and Chk2 mRNA expression was evaluated 
in 41 (76%) newly diagnosed BCR-ABL1-positive (median age 56 years, range 26-81; ratio 
male/female: 20/21) and 13 (23%) newly diagnosed BCR-ABL1-negative ALL cases (median age 
41 years, range 18-69; ratio male/female: 5/8). One microgram of RNA was reverse transcribed 
using the High Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA). PCR analysis was 
performed using HS00967506_m1 (Chk1) and HS00200485_m1 (Chk2) assays (Applied 
Biosystems) and the Fluidigm Dynamic Array 48 x 48 system, a real-time quantitative 
polymerase chain reaction (qPCR) assay which enables to automatically assemble 48 samples 
and 48 assays to create individual TaqMan reactions of a final volume of 6.75 nanolitres each 
(Fluidigm, San Francisco, CA, http://www.fluidigm.com/). RNA integrity was confirmed by PCR 
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amplification of the GAPDH mRNA (Hs99999905_m1), which is expressed ubiquitously in 
human hematopoietic cells. Results were expressed as 2exp(-ΔΔCt). GraphPad Prism 5 software 
(GraphPad, Avenida de la Playa La Jolla, CA USA) was used to plot the data. The basal mRNA 
expression of Chk1 and of Chk2 was evaluated in all the cell lines using the same assays 
(Applied Biosystems: HS00967506_m1 Chk1 and HS00200485_m1 Chk2) used for the primary 
samples and the statistical validity of the results were confirmed using ANOVA multiple 
comparisons test (GraphPad Prism 5 software) In addition, reverse transcription and 
quantitative-PCR analysis for GADD45a, PLK3, CDK4 and CHK2 in treated cell lines and on their 
untreated counterpart were performed as upper described using the following assays from 
Applied Biosystems: Hs00169255_m1 (Gadd45a), Hs00177725_m1 (PLK3), Hs00262861_m1 
(CDK4) and HS00200485_m1 (Chk2).  
 
TP53 mutation screening 
Total cellular RNA was extracted using the RNeasy total RNA isolation kit (Qiagen, Valencia, CA). 
One microgram of total RNA was reverse transcribed using the M-MLV Reverse Transcriptase 
(Invitrogen, San Diego, CA). Three overlapping shorter amplicons [amplicon 1 (491 bp): exons 1-
5; amplicon 2 (482 bp): exons 5-8; amplicon 3 (498 bp): exons 8-11)] covering the entire TP53 
coding sequence (GenBank accession number NM_000546.4) were amplified with 2U of 
FastStart Taq DNA Polymerase (Roche Diagnostics, Mannheim, Germany), 0.8 mM dNTPs, 1 mM 
MgCl2, and 0.2 M forward and reverse primers (Table 3S) in 25 μl reaction volumes. PCR 
products were purified using QIAquick PCR purification kit (Qiagen) and then directly 
sequenced using an ABI PRISM 3730 automated DNA sequencer (Applied Biosystems, Foster 
City, CA) and a Big Dye Terminator DNA sequencing kit (Applied Biosystems). All sequence 
variations were detected by comparison using the BLAST software tool 
(www.ncbi.nlm.nih.gov/BLAST/) to reference genome sequence data (GenBank accession 
number NM_000546.4). 
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Immunohistochemistry  
Studies evaluating Chk1, phosphorylated Chk1 (Ser345), Chk2, phosphorylated Chk2 (Thr68) 
CDc25C, phosphorylated Cdc25C (Ser216) and phosphorylated H2A.X (Ser139) (γ-H2A.X) 
proteins expression were performed on FFPE samples corresponding to three thymuses, three 
reactive lymph nodes and to primary tumours collected from 60 ALL patients at diagnosis, 
including 36 B-ALL (median age 50 years, range 5-86; ratio male/female: 18/18)  and 24 T-ALL 
(median age 38 years, range 2-76; ratio male/female: 15/9). All the cases were retrieved from 
the archives of the Haematopathology Unit, Department of Experimental, Diagnostic and 
Specialty Medicine - DIMES, University of Bologna. The study was conducted according to the 
principles of the Helsinki declaration after approval of the Internal review Board. Two different 
tissue-microarrays (TMAs) were constructed from these paraffin-embedded blocks as 
previously reported. TMAs sections were investigated by antibodies raised against fixation 
resistant epitopes. The antibody reactivity and sources as well as the antigen retrieval 
protocols, dilutions and revelation systems are detailed in Table 4S. A cut-off of staining > 30% 
of the examined cells was assigned as positive score, according to formerly defined 
criteria[117]. Immunohistochemical preparations were visualized and images were captured 
using Olympus Dot-slide microscope digital system equipped with the VS110 image analysis 
software. 
 
Primary cells 
Primary blast cells from 14 newly diagnosed ALL cases were obtained, upon written informed 
consent, from bone marrow and peripheral blood samples by density gradient centrifugation 
over Lymphoprep (Nycomed UK, Birmingham). 10 (71%) samples were from adults with BCR-
ABL1-positive ALL (median age 51 years, range 25-74 years; median blast percentage 92%, 
range 60-100%) and 4 (29%) from patients with BCR-ABL1-negative ALL (median age 34 years, 
range 18-43 years; median blast percentage 93%, range 90-100%). Main patient’s 
characteristics are given in Table 1S.  
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Normal bone marrow progenitors were harvested from bone marrow aspirations performed in 
lymphoma patients undergoing initial staging procedures, which then resulted negative for 
lymphoma infiltration. Normal peripheral blood progenitors were harvested from healthy 
donors. 
 
Cell viability assay 
In order to assess the cell viability after treatment with PF-00477736 (Pfizer), ALL cell lines were 
seeded in 96-well plates at 50,000 cell/100 μl/well with increasing concentrations of drug 
(0.005-2 μM) for 24 and 48 hours and incubated at 37°C. Cell viability was assessed by adding 
WST-1 reagent (Roche Applied Science, Basel, Switzerland) to the culture medium at 1:10 
dilution. Cells were incubated at 37°C and the optical density was measured by microplate 
ELISA reader at λ450 after 3 hours. The amount of the formazan formed directly correlates to 
the number of metabolically active cells. All viability experiments were performed in triplicates 
and repeated in least two separated experiments. In ex-vivo primary leukemia cells the effects 
on cell viability was assessed by counting viable and non-viable cell numbers by the Trypan blue 
dye exclusion method. Cells were seeded in 6-well plates at 500,000 cell/1 ml with increasing 
concentrations of drug (0.1, 0.5 and 1 μM) for 24 hours and incubated at 37°C. Cellular viability 
was calculated as a percentage of the viable cells compared to the untreated controls (DMSO 
0.1%).  
 
Annexin V staining of apoptotic cells 
According to the WST-1 results, three different increasing concentrations of PF-00477736 were 
used to treat leukemia cells lines in order to detect and discriminate apoptotic, necrotic and 
dead cells. Cell lines were seeded in 12-well plates at 500,000 cell/1 ml with increasing 
concentrations of drug (0.1, 0.5 and 1 μM and 0.05, 0.1 and 0.2 μM only for BV-173 and RPMI-
8402) for 24 and 48 hours and incubated at 37°C. Following the treatment, cells were harvested 
and stained with Annexin V/Propidium Iodide (PI) according to the manufacturer's instruction 
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(Roche). The percentage of Annexin V-PI positive cells was determined within 1 × 104 cells of 
the population by flow cytometry (Facs CantoII, BD Biosciences Pharmingen, San Jose, 
California, USA). The mean percentage of Annexin V-PI positive cells and standard error 
measurement was calculated from at least two separate experiments. 
 
Western Blot analysis 
To gain insight into the molecular mechanisms responsible for cell death following treatment, 
functional analyses by western blot were performed. Leukemia cell lines were plated in 6-well 
plates at 500,000 cell/1 ml with increasing concentrations of drug for 24 hours and incubated at 
37°C. After the treatment, the cells were collected and lysate using a specific buffer made of 
KH2PO4 0,1 M (pH 7,5), Igepal 1% (NP-40), β-glicerofosfato 0,1 mM and complete protease 
inhibitor cocktail 1X (Roche Diagnostics).For each sample 30ug of protein were fractioned on 
Mini-Protean TGX stain-free precasted gels, blotted to nitrocellulose membranes (Bio-Rad 
Trans-blot turbo transfer pack) and incubated overnight with the following antibodies: ATM 
(#2873S), phosphorylated ATM (Ser1981)(#5883S), ATR (#2790S), phosphorylated ATR 
(Ser428)(#2853S), Chk1 (#2345S), phosphorylated Chk1 (Ser317)(#2344S), phosphorylated Chk1 
(Ser296)(#2349) and Chk1 (Ser345)(#2348S), Chk2 (#2662S), phosphorylated Chk2 
(Thr68)(#2661S), Cdc25c (#4688S), phosphorylated Cdc25C (Ser216)(#9528S), Parp-1 (#9542), 
Cdc2 (#9112S), phosphorylated Cdc2 (Tyr15)(#4539S), phosphorylated H2A.X (Ser139) (γ-H2A.X) 
(#2577S), from Cell Signaling. Antibody to β-actin came from Sigma (St. Louis, MO). Finally all 
these antibodies were detected using the enhanced chemiluminescence kit ECL (GE) and the 
compact darkroom ChemiDoc-It (UVP).  
Immunofluorescence analysis 
NALM-6 and BV-173 cells were seeded to poly-D lysine-coated slides, fixed with 4% PFA 
(Paraformaldehyde) and stained at 37°C with a mouse anti-H2A.X-Phosphorylated Alexa 647 
conjugated antibody (BioLegend). Then they were treated with DAPI (4.6 diamidino-2-
phenylindole; Sigma Aldrich) and the slides were mounted with Mowiol (Calbiochem). Images 
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were acquired with wide field fluorescence microscope Olympus BX61 fully motorized driven by 
Metamorph software and the analysis was performed using the freeware ImageJ software. 
 
Gene expression profiling 
Gene expression profiling on treated and untreated cells (DMSO 0.1%) after 24 hours of 
exposure to PF-0077736 were performed using Affymetrix GeneChip Human Gene 1.0 ST 
platform (Affymetrix Inc. Santa Clara, California, USA) and following manufacturers’ 
instructions. Raw data were normalized by using the RMA algorithm and filtered. Genes 
differentially expressed were selected by analysis of variance (ANOVA) (p-value threshold = 
0.05) using the Partek Genomics Suite software (Partek Incorporated Saint Louis, MO 63005, 
USA, http://www.partek.com). The most significantly involved process networks were defined 
by the Metacore software (GeneGo Inc., www.genego.com). 
Cell cycle analysis 
In order to evaluate the effect of PF-00477736 on cell cycle progression, NALM-6, SUPB-15, 
RPMI-8402 and BV-173 cell lines were seeded in a 24 wells plate at 500,000 cell/1 ml with 
increasing concentrations of PF-00477736 (respectively 0.1, 0.5 and 1 μM for NALM-6 and SUP-
B15; 0.05, 0.1 and 0.2 μM for RPMI-8402 and BV-173). After 6 and 24 hours cells were 
harvested and fixed overnight using ethanol at 70%. Then cells were stained using PI/RNase 
Staining Buffer according to the manufacturer's instruction (BD Pharmingen) and the cell cycle 
profile was detected using FACSCanto II instrument. The percentage of the different cell cycle 
phases was performed using the DNA cell-cycle analysis software for flow cytometry data, 
ModFit LT (Verity). 
In vivo Studies 
Experiments involving mice were performed in agreement with Italian guidelines and after the 
approval of the Institutional Review Board of the European Institute of Oncology. Leukemic 
mice were generated by a single administration of the tumorigenic agent N-ethyl-N-nitrosourea 
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(ENU, Sigma, 50mg/kg intraperitoneally). Spleen cells from leukemic C57BL6/Ly5.2 mice were 
injected intravenously (2×106 cells/mouse) into non irradiated, recipient C57BL6/Ly5.1 mice. 
PF-0077736 was administered intraperitoneally starting from day 3 after the transplant of 
leukemic cells. Mice received doses of PF-0077736 (40mg/kg each dose) every three days for 
four treatments (q3dx4). Kaplan-Meyer rank test was used to compare the survival rate 
between treated and control mice. 
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Figure 1S: Basal expression of Chk1 and Chk2 (mRNA level) in the cell lines treated, the results 
are expressed as 2exp(-ΔΔCt) (A). Schematic representation of the statistically significance of 
the ANOVA multiple comparison test in which the basal expression of each cell lines is 
compared to the value of the basal expression of all the other cell lines. In the legend on the 
right the increasing statistical significance of the analysis is showed with different color: bright 
yellow (p value <0.05), dark yellow (p value <0.01), bright red (p value <0.001), dark red (p value 
<0.0001) and gray (no statistical significance of the comparison). For the ANOVA analysis of the 
basal expression of Chk1 and of Chk2 for each cell lines were compared, respectively six and 
four different replicates (B). 
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Figure 2S: Oncomine expression analysis of Chk1 (A) and Chk2 (B) levels between normal 
monunuclear cells (MNCs) from bone marrow and different subtypes of leukemia (AML, B-ALL, 
T-ALL). Expression values are log transformed and median centered per array. Differential 
expression is identified by a permutation test and P values are calculated by t test and 
corrected for multiple comparisons by the method of false discovery rates. The group with the 
highest p-value is highlighted in blue. Chk1 transcript levels between normal MNCs and 
leukemia samples are extracted from the study of Andersson A et al [Leukemia. 2007 
Jun;21(6):1198-203]. Dot points indicate the minimum and the maximum values in each 
dataset.  
 
Figure 3S: Apoptosis following treatment with PF-00477736 at 24 and 48 hours in B-ALL and T-
ALL cells. The Annexin V/PI staining analysis showed increase of apoptosis at 24 and 48 hours in 
B-ALL cell lines proportional to drug-dose and drug-exposure time. These graphs reproduce the 
mean of two independent experiments (A). Cell cycle analysis of RPMI-8402, BV-173, SUP-B15 
and NALM-6 cell lines treated for 24 hours with increasing concentrations of PF-00477736. 
RPMI-8402 
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Figure 4S: Western Blot analysis in all leukemia cell lines after exposure to PF-00477736 (+) at 
the concentration closest the IC50 or DMSO 0.1%(-) (A). Western Blot analysis of BV-173 and 
NALM-6 cell lines treated with or without PF-00477736 (IC50) for 3, 6 and 9 hours (B). 
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Figure 5S: Cell cycle_ESR1 regulation of G1/S transition: the top scored map (map with the 
lowest p-value) based on the enrichment distribution sorted by 'Statistically significant Maps' 
set. Experimental data is linked to and visualized on the maps as thermometer-like figures. 
Up-ward thermometers have red color and indicate up-regulated signals and down-ward (blue) 
ones indicate down-regulated expression levels of the genes 
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Figure 6S: Apoptosis and survival_Granzyme A signaling: the second scored map (map with the second 
lowest p-value) based on the enrichment distribution sorted by 'Statistically significant Maps' set. 
Experimental data is linked to and visualized on the maps as thermometer-like figures. Up-ward 
thermometers have red color and indicate up-regulated signals and down-ward (blue) ones indicate 
down-regulated expression levels of the genes. 
 
 
59 
 
Figure 7S: DNA damage_ATM/ATR regulation of G1/S checkpoint: the third scored map (map 
with the third lowest p-value) based on the enrichment distribution sorted by 'Statistically 
significant Maps' set. Experimental data is linked to and visualized on the maps as 
thermometer-like figures. Up-ward thermometers have red color and indicate up-regulated 
signals and down-ward (blue) ones indicate down-regulated expression levels of the genes. 
 
Figure 8S: Protein expression level of c-Jun in B-/T-ALL cell lines. The treatment with PF-
00477736 increases the expression of c-Jun in all B-ALL cell lines but not in all T-ALL cell lines 
(A). Western Blot analysis of Normal MNCs and ALL MNCs after exposure to PF-00477736. 
Normal MNCs (#144, #145, #146 and #149) and ALL MNCs samples were exposed to PF-
00477736 at the concentration of 1000 nM for 24 hours. For each sample 30 ug of protein were 
loaded and for housekeeping β-Actin was used (B). mRNA expression of CDK4, Chk2, Gadd45a 
and PLK3 in B-/T-ALL cell lines treated with or without PF-00477736(IC50 value) for 24 hours. 
The results are expressed as 2exp(-ΔΔCt)(C).  
Table 1. Immunohistochemical results.  Abbreviation: pos means number of positive 
cases/number of evaluable cases. 
Tumor 
Type 
Chk1 pChk1 Chk2 pChk2 CDc25C pCDc25C γH2A.X 
pos (%) pos (%) pos (%) pos (%) pos (%) Pos (%) pos (%) 
ALL 51/54 (94) 45/56 (80) 55/57 (96) 15/55 (27) 57/57 (100) 38/55 (70) 40/59 (68) 
B-ALL 31/31 (100) 28/33 (85) 32/33 (97) 11/32 (33) 34/34 (100) 23/32 (72) 25/36 (69) 
T-ALL 20/23 (87) 17/23 (74) 23/24 (96) 4/23 (17) 23/23 (100) 15/23 (65) 15/23 (65) 
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Abstract 
During the last few years many Chk1/Chk2 inhibitors have been developed for the treatment of 
different type of cancer. In this study we evaluated the efficacy of the Checkpoint kinase 1/2 
inhibitor, LY2606368 mesylate monohydrate, in B-/T-ALL as single agent and in combination 
with other drugs. The LY2606368 deeply reduced the cell viability in a dose and time dependent 
manner in all the treated cell lines. The cytotoxic activity was confirmed by the increment of 
apoptotic cells (Annexin V/Propidium Iodide staining), by the increase of γH2A.X protein 
expression and by the activation of different apoptotic markers (Parp-1 and pro-Caspase3 
cleavage). Furthermore, the inhibition of Chk1 deeply changed the cell cycle profile. In order to 
evaluate the chemo-sensitizer activity of the compound, different cell lines were treated for 24 
and 48 hours with LY2606368 in combination with other drugs (imatinib, dasatinib and 
clofarabine). The results from cell line models were strengthened in primary leukemic blasts 
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isolated from peripheral blood of adult acute lymphoblastic leukemia patients. In this study we 
highlight the mechanism of action and the effectiveness of LY2606368 as single agent or in 
combination with other standard drugs like imatinib, dasatinib and clofarabine in the treatment 
of B-/T-ALL.  
 
Introduction 
Nowadays the efficacy of treatments for adult Acute Lymphoblastic Leukemia (ALL) is still very 
poor with the exception of particular sub-types, like the BCR-ABL1 positive once (Philadelphia-
positive), which are successfully treated with targeted drugs, like the tyrosine kinase inhibitors 
(TKIs)[118,119]. Although enormous progresses have been done in the treatment of ALL, 
several sub-types continue to have a very poor prognosis due to not adequate treatment. 
Moreover a large percentage of patients, initially successfully treated, develop resistance to 
treatment and consequently relapses. Thus, there is a need to improve therapeutic approaches. 
Recently, many international research groups have focused their studies on the potential 
efficacy of the inhibition of specific kinases involved in the regulation of the cell cycle and in the 
DNA damage response (DDR)[120]. In all eukaryotic cells, the cell cycle, is finely regulated by 
three different checkpoints (G1/S, intra-S and G2/M checkpoints) that control the transition 
from a specific phase of the cell cycle to another [121]. The G1/S checkpoint is mainly 
controlled by the tumor-suppressor p53[122] that regulates the transition through the G1 
phase by enhancing the transcription of p21Waf1/Cip1 protein, a cyclin-dependent kinase (Cdk) 
inhibitors [123]. The transition through the S and the G2/M phase is regulated by Checkpoint 
kinase 1 (Chk1) and at a lower rate by Checkpoint kinase 2 (Chk2). Chk1 and Chk2 are two 
serine-threonine kinases involved in the response to DNA damages and, in particular, in the 
response to Single Strand Breaks (SSBs) and Double Strand Breaks (DSBs) of the DNA[124]. 
Numerous stimuli, like Ionizing Radiation (IR), X-ray exposure, replicative stress and 
chemotherapy drugs, activates Chk1/Chk2 response[125]. Chk1 and Chk2 are activated, via 
phosphorylation, respectively by ataxia telangiectasia and Rad3-related (ATR) and by ataxia 
telangiectasia mutated protein (ATM)[126–128]. As consequence of their activation, both 
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Chk1/Chk2 arrest the cell cycle, activate DNA damages repair and promote cell death via 
apoptosis. Although no hereditary mutations of Chk1 or Chk2 have been found to promote 
tumor transformation, in numerous type of cancer the expression of these kinases have been 
found altered. In particular in many tumors the over-expression of Chk1 has been related to the 
resistance to treatments and to the increase of genetic instability. Due to their biological 
relevance, numerous checkpoint kinases inhibitors (Chk-i) have been developed in order to 
potentiate the efficacy of different antineoplastic drugs and to increase the cytotoxicity of 
radiotherapy [57,129–131,60,132,133]. Currently although the number of publications and of 
clinical trials regarding the evaluation of the efficacy of Chk-i in solid tumor is in constantly 
growth [19,20], only few studies have been done to demonstrate their efficacy in the treatment 
of hematologic malignancies [132] and even a lower number specifically in ALL[133]. Our group 
has recently published the efficacy in single agent of PF-0477736, a small Chk1/Chk2 inhibitor, 
on a panel of different B-/T-ALL cell lines and on primary leukemic cells isolated from adult B-
ALL patients. The results of the study showed that Chk1 kinase, but not Chk2, was significantly 
over-expressed in ALL patients in comparison to normal mononuclear cells and that the 
inhibition of Chk1/Chk2 functionality was enough to deeply reduced the cell viability and 
induced apoptosis on ALL primary cells and cell lines [133]. Starting from this background, in 
this study, we evaluated the in vitro efficacy of the LY2606368 mesylate monohydrate 
(hereafter referred to LY2606368), a novel Chk1/Chk2 inhibitor, in B- and T-progenitor ALL as 
single agent or in combination with different drugs like TKIs and other chemotherapy drugs like 
purine nucleoside analogue clofarabine. The LY2606368 is a small molecule that acts as a 
selective ATP competitor inhibitor of Chk1 and Chk2[135] proteins. Recently, the in vitro/in vivo 
effectiveness of the compound as a chemo sensitizer agent was assessed on different kinds of 
tumor models[76]. Nowadays this molecule is part of a clinical phase I study in patients with 
advance cancer as single agent, NCT01115790, and in combination with other chemotherapy 
drugs or radiotherapy (NCT02124148, NCT02555644). The chemo-sensitizer activity, in term of 
abrogation of the cell response to DNA damages, was evaluated combining LY2606368 with 
different compounds normally used in the clinic of adult ALL patients[136]. In particular 
Philadelphia-positive cell lines and primary leukemic cells were treated combining LY2606368 
64 
 
with two TKIs (imatinib and dasatinib). The efficacy of both TKIs have been well established for 
the treatment of ALL harboring the fusion protein BCR-ABL1[137]. Philadelphia-negative cell 
lines were treated with LY2606368 and with the 2’-deoxyadenosine analogue, clofarabine. 
Clofarabine has been showed to induce cell apoptosis due to the reduction of nucleoside 
triphosphate and consequently due to the inhibition of ribonucleotide reductase and DNA 
polymerases[138,139].  
 
Results 
LY2606368 inhibits the cell viability in B-/T-ALL cell lines 
The efficacy of the compound, in term of reduction of the cell viability, was firstly evaluated on 
a panel of different B-/T-ALL cell lines (BV-173, SUP-B15, REH, NALM-6, NALM-19, MOLT-4, 
RPMI-8402 and CCRF-CEM). In order to evaluate the cytotoxicity of the compound, all the cell 
lines were incubated for 24 and 48 hours with increasing concentration of LY2606368 (1-100 
nM ). The compound reduced the cell viability in all the treated cells in a time and dosage-
dependent manner. Using specific statistical analysis, the IC50 values were detected for all the 
cell lines highlighting the BV-173 as the most sensitive cell line (6.33nM) and the REH as the less 
sensitive( 96.7 nM). The sensitivity to the compound as single agent did not correlate with 
leukemia cell type (B-ALL vs T-ALL), with the mutational status of the onco-suppressor p53 (BV-
173, SUPB-15, NALM-6 and NALM-19 cells are p53 wild-type whereas REH, MOLT-4, RPMI-8402 
and CEM cells are p53 mutated) (Fig. 1A; Table 1) or with the basal expression of Chk1 or Chk2 
proteins (data not showed). The correlation between the mutational status of p53 and the 
sensitivity to the compound was evaluated because of its role in the regulation of the G1-S 
checkpoint and in the response of DNA damages [38,39]. 
LY2606368 as single agent activates the apoptotic cascade in B-/T-ALL cell lines 
In order to better investigate the mechanism of action of LY2606368 and to correlate the 
inhibition of cell viability with the induction of the cell death, different Annexin V/Propidium 
iodide (Pi) staining analyses were performed. Cells were treated for 24 and 48 hours with 
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increasing concentration of LY2606368 (BV-173 and RPMI-8402: 2, 7.5 and 15 nM; NALM-6, 
NALM-19 and MOLT-4: 7.5, 15 and 30 nM; SUP-B15, REH and CCRF-CEM: 50, 100 and 200 nM) 
and the number of apoptotic and necrotic cells was evaluated using cytofluorometry. In line 
with the results found in the cell viability assays, the treatment enhanced cell death via 
apoptosis and the amount of apoptotic and necrotic cells was time and dosage-dependent in all 
the treated cell lines (Fig. 1C). The activation of the apoptotic cascade was confirmed by 
Western blot as showed by the cleavage of the apoptotic marker, poly (ADP-ribose) polymerase 
1(PARP1) (Fig. 1D). 
LY2606368 modifies the cell cycle profile and targets the Chk1 pathway in B-/T-ALL cell lines 
In order to evaluate the consequences the inhibition of Chk1 on cell cycle progression, different 
cell cycle analyses were performed. To this purpose cells were treated with LY2606368 (doses 
nearest to IC50 values) for 24 hours and then stained for 1 hour with Propidium Iodide (Pi). The 
inhibition of Chk1, although with heterogeneity among the different cell lines, deeply changed 
the cell cycle profile. In agreement with the study of King C. and colleagues[76] the treatment 
with LY2606368 reduced the amount of cells in G1 and G2/M phase while increased the 
number of cells in early S phase (Fig.1B). Subsequently the results found on the cell cycle profile 
analyses were correlated with the modifications of the expression of different proteins of the 
Chk1 pathway. To this purpose cells were treated with LY2606368 (doses nearest to IC50 values) 
for 24 hours and then stained for different markers. First of all the inhibition of Chk1 
functionality, marker of the on-target activity of the compound, was confirmed by the 
reduction of the phosphorylated isoform of Chk1 (ser296 auto-phosphorylation site). The 
treatment with LY2606368 modified different key elements the Chk1 pathway most of them 
involved in the regulation of the G2/M checkpoint. In particular the alteration of the number of 
cells in G2/M phase seen in the cell cycle analysis was confirmed by the reduction of both basal 
and phosphorylated isoforms of the phosphatase Cdc25C (phospho-Cdc25Cser216) and of the 
kinase cyclin-dependent, Cdc2 (phospho-Cdc2Tyr15). No significant changes have been found on 
the amount of the basal forms of both Cdc25A and Cdc1. To deeply investigate the effect of 
Chk1 inhibition in term of induction of DNA damages, cells were stained for the following 
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antibodies: phospho-Chk1 ser317, marker of activation of the Chk1 pathway; γ-H2A.X, marker of 
DNA damages; Parp-1, marker of induction of apoptosis. In all the cell lines the induction of 
DNA damage after the treatment was confirmed by increment of both phospho-Chk1ser317 and 
γ-H2A.X, while the activation of apoptosis was confirmed by the cleavage of Parp-1. Finally in 
order to highlight if the increment of the DNA damages and the activation of the apoptosis 
could be related with the induction of cell death by mitotic catastrophe, the expression of the 
phosphorylated isoform of the histone H3 (phospho-HH3ser10), marker of mitosis, was 
evaluated. In all cell lines, with the exclusion of RPM-8402 and MOLT-4 cells, the expression of 
phospho-HH3ser10 was reduced by the treatment excluding the hypothetic mechanism of cell 
death through the mitotic catastrophe (Fig 1D). This data was confirmed also by flow cytometry 
in REH and NALM-6 cell lines. Cells were treated for 18, 24, 30 and 48 hours and then co-
stained using Pi with a primary conjugated antibody, phospho-HH3ser10 (FITC-conjugated). In 
line with the result found in the Western blot analysis, the treatment reduced the amount of 
cells positive for the pHH3ser10 in both the cell lines (Fig.S1D). The effect of LY2606368 on cell 
cycle progression was also analyzed at different time points. In particular, BV-173, NALM-6 and 
REH cell lines were treated with LY2606368 (respectively, with 7.5, 30 and 100 nM) for 18, 24, 
30 and 48 hours and then stained with Pi (Fig.S1A). Again the consequences of the inhibition of 
the Chk1 pathway was also analyzed using Western blots analysis. These experiments 
highlighted that the effects of Chk1 inhibition were time-dependent, especially in term of the 
induction of DNA damages (γ-H2A.X) (Fig. S1B). The hypothetical mechanism of action of the 
compound in term of perturbation of cell cycle checkpoint functionality and in term of 
progressively accumulation of DNA damages is graphically showed in Figure 5. 
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Figure 1: Effect of LY2606368 on cell viability, induction of apoptosis, inhibition of Chk1 
pathway and cell cycle profile in B-/T-ALL cell lines. Graphical representation of the IC50 values 
of the B-/T-ALL cell lines after 24 and 48 hours of incubation with LY2606368. The IC50 values 
were obtained from two independent experiments (A). Cell cycle profile of B-/T-ALL cell lines 
treated with or without LY2606368 (IC50 value) for 24 hours (B). Graphical representation of 
apoptosis induction by LY2606368. BV-173, NALM-6 and REH cells were treated with increasing 
concentration of drug for 24 and 48 hours (C). The blots show, for each cell lines, the expression 
of key elements of the Chk1 pathway after 24 hours of incubation with LY2606368 (IC50 value) 
(D). In the figure the samples named Control were cells treated with 0.1 % of DMSO. In the 
Western blot analysis the homogeneity of the protein loaded (30 g) was determined by using 
an internal control (β-actin). 
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LY2606368 increase the cytotoxicity of different Tyrosine kinase inhibitors (TKis) in Philadelphia-
positive cell lines 
In order to assess the chemo-sensitizer ability of LY2606368, different experiments combining 
the Chk1/Chk2 inhibitor with different compounds, normally used in the clinic, were 
performed. To this purpose two Philadelphia-positive cell lines were treated for 24 and 48 
hours with LY2606368 (BV-173 7.5 nM; SUP-B15 50 nM) in combination with two different 
tyrosine kinase inhibitors (TKIs), imatinib (BV-173 500 nM; SUPB15 10 M) and dasatinib (BV-
173 50 nM; SUP-B15 500 nM), and the reduction of the cell viability was evaluated using WST-1 
reagent. In both the treated cell lines the combinations increased the cytotoxicity of the two 
TKIs in comparison the effect of the single treatments (Fig. 2A).Then to deeply understand the 
chemo-sensitizer activity of the compound and to evaluate the effect of the combination 
between LY2606368 and TKIs using sub-toxic concentrations, different combination index 
assays were performed. BV-173 and SUP-B15 cell lines were incubated with increasing 
concentration of LY2606368 (BV-173: from 0.6 to 10 nM, dilution rate 1:2; SUP-B15: from 6.25 
to 100 nM, dilution rate 1:2) and two increasing concentration of imatinib (BV-173: 250 and 500 
nM; SUP-B15: 5 and 10 M) for 24 and 48 hours. For instance in BV-173 after 24 hours of single 
treatment with LY2606368 (5 nM) and imatinib (250 nM), the percentage of living cells was 
close respectively to the 50 % and 65 %, but in the samples with the combined drugs was less 
than 23 % (Fig.2C). The consequences of the co-treatment, in term of change in the expression 
of different key elements of the Chk1 pathway, were investigated using Western blot. BV-173 
cell line was incubated with LY2606368 (7.5 nM) and with or without the two TKIs (imatinib: 
500 nM; dasatinib: 50 nM) for 24 hours. The single treatments with the TKIs as well as their 
combinations with LY2606368 did not significantly change the key elements of the Chk1 
pathway. However in term of induction of DNA damages (H2A.X ) the co-treatment resulted in 
an additive effect in both the combinations (Fig. 2B). 
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Figure 2: Effect of LY2606368 in combination with TKIs in Philadelphia-positive cell lines. Cell 
viability analysis of BV-173 and SUP-B15 cell lines incubated with LY2606368 and TKIs (imatinib 
and dasatinib) for 24 and 48 hours. For each cell lines three different experiments have been 
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performed (A). The blot shows the expression different proteins of the Chk1 pathway after 24 
hours of incubation with LY2606368 in combination with the two TKIs. The cell line BV-173 was 
incubated with: LY2606368: 7n; imatinib: 500nM; dasatinib: 50nM (B). Combination index 
analysis of BV-173 and SUP-B15 cell lines incubated with increasing concentration of LY2606368 
(BV-173: from 10 to 0.6 nM, dilution rate 1:2; SUP-B15: from 100 to 6.25 nM, dilution rate 1:2) 
and two increasing concentrations of imatinib (BV-173: 250 and 500 nM; SUP-B15: 5 and 10 
M) for 24 and 48 hours. The black curve (control) represents the effect of the LY2606368 
alone while the two red curves represent the two combinations (full square LY2606368 + 250 
nM (BV-173) or +5 M (SUP-B15) of imatinib; full triangle LY2606368+ 500 nM (BV-173) or 
-B15) of imatinib). The curves represent the mean of two independent experiments 
(C). In the figure the samples named Control were cells treated with 0.1 % of DMSO.  In the 
Western blot analysis the homogeneity of the protein loaded (30 g) was determined by using 
an internal control (β-actin). 
 
LY2606368 increases the cytotoxicity of clofarabine in Philadelphia-negative cell lines 
The efficacy as chemo-sensitizer agent of the compound on Philadelphia-negative B-/T-ALL cell 
lines was evaluated combining the Chk1/Chk2 inhibitor with the purine nucleoside 
antimetabolite clofarabine, which is commonly used in clinical trials for the treatment of young 
and adult ALL patients[140,141]. The effect of clofarabine in term of reduction of the cell 
viability was evaluated using WST-1 and for each cell lines was calculated the IC50 value (data 
not showed). The effect of the combination was very heterogeneous between the different cell 
lines (Fig.3A). Interestingly no significant differences in term of effectiveness of the 
combination was seen between cell lines with p53 mutated, that should have an impaired 
function of the G1/S checkpoint, and with p53 wild type (Table 1). To deeply investigate the 
effect of the combination of this two drugs and to evaluate if the cytotoxic effect could be 
dependent to a particular schedule, different experiments were performed. For this reason 
NALM-6 and REH cell lines were treated respectively with clofarabine alone for 48 hours (50 
nM), LY2606368 alone for 48 hours (10 nM), pre-incubated with clofarabine for 24 hours and 
then with LY2606368 for 24 hours or pre-incubated with LY2606368 for 24 hours and then with 
clofarabine for 24 hours. No significant differences were found between the different schedules 
(Fig. S1C). As with the previous combinations with TKIs, the consequences of the combination 
on the Chk1 pathway were evaluated using Western blot analysis. REH and NALM-6 cell lines 
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were incubated for 24 hours with the checkpoint inhibitor in combination with clofarabine 
using for each drugs the dose nearest to the IC50 after 24 hours (clofarabine: 50 nM; 
LY2606368. respectively 100 and 30 nM). The treatment with clofarabine in single agent did not 
significantly change the protein level of the main downstream targets of Chk1, except for the 
amount of γ-H2A.X. However the combination of the two drugs, in both the cell lines, changed 
the levels of expression of different proteins involved in the Chk1 pathway. In particular the co-
treatment increased the DNA damages (γ-H2A.X) and the activation of the apoptosis (Parp-1 
and pro-Caspase 3 cleavage) when compared with the cytotoxic effect of the single drugs (Fig. 
3B). The ability of LY2606368 to sensitize leukemic cell lines to the cytotoxicity of clofarabine 
was evaluated performing different combination index analyses. To this purpose NALM-6 and 
REH cell lines were incubated with increasing concentration of LY2606368 (from 0 to 100 nM 
dilution rate 1:2) and with two different concentrations of clofarabine (sub-toxic concentration: 
5 and 10 nM ) for 24 and 48 hours. In both the cell lines the reduction of the cell viability was 
additively stronger in the samples treated with the two compounds than in the samples treated 
with the two drugs in single agent. For instance in NALM-6 cell line the percentage of living cells 
in the sample treated with 12.5 nM of LY2606368 for 48 hours was respectively close to 90%, in 
the sample treated with 10 nM of clofarabine for 48 hours was close to 54% and in the samples 
with the combined drugs was less than 25% (Fig.3C). 
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Figure 3: Effect of LY2606368 in combination with clofarabine in Philadelphia-negative cell 
lines. Cell viability analysis of Philadelphia-negative ALL cell lines incubated LY2606368 and 
clofarabine for 24 and 48 hours. For each cell lines three independent experiments have been 
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performed (A). The blots show the expression on NALM-6 and REH cell lines of different 
proteins of the Chk1 pathway after 24 hours of treatment with LY2606368 in combination with 
clofarabine. The dosages of each drug have been chosen based on the IC50 values after 24 hours 
of incubation (B). Combination index assay of NALM-6 and REH cell lines treated with increasing 
concentration of LY2606368 (from 1.5 to 100 nM) and sub-toxic concentration of clofarabine (5 
and 10 nM). The black curve (Control) represents the effect of the LY2606368 alone while the 
two red curves represent the effect of the combinations (full triangle LY2606368 + 5 nM of 
clofarabine; full square LY2606368+10 nM of clofarabine) after 48 hours of incubation with the 
two drugs. The curves in graph are representative of the mean of two independent experiments 
(C). In the figure the samples named Control were cells treated with 0.1 % of DMSO. In the 
Western blot analysis the homogeneity of the protein loaded (30 g) was determined by using 
an internal control (β-actin).
 
LY2606368 targets the Chk1 pathway on leukemic blasts but not on peripheral blood 
mononuclear cell of healthy donors 
Finally the effectiveness of the compound was evaluated on different primary leukemic cells 
isolated from the bone marrow and the peripheral blood of 9 adult B-ALL patients and on the 
mononuclear cells isolated from the peripheral blood of 5 healthy donors. To this purpose the 
primary cells were treated with increasing concentration of LY2606368 (100, 200 and 500 nM) 
for 24 hours and then the reduction of the cell viability was evaluated using Trypan blue 
exclusion dye method. Similarly to the results found on B-/T-ALL cell lines, LY2606368 
progressively reduced the cell viability in a dose-dependent manner in all the primary leukemic 
cells (Fig. 4A).The sensitivity to the compound was not related with the leukemia sub-types (Fig 
S1E). However on the mononuclear cells isolated for the healthy donors the treatment did not 
reduced significantly the cell viability (Fig. 1E). To correlate the reduction of the cell viability 
with the induction of DNA damages, the primary cells isolated from the bone marrow of 4 adult 
B-ALL patients were treated with a sub-toxic concentration of the compound (100 nM) and then 
stained for phospho-Chk1ser317, Chk1 and H2A.X. The Western blot analysis showed that in all 
the samples, although with a high heterogeneity, the treatment with LY2606368 increased both 
the two markers of DNA damage (phospho-Chk1 ser317and H2A.X) (Fig.4B). By contrast, in 
normal cells, isolated form the peripheral blood of 5 healthy donors, the effect of the 
compound did not reduced significantly the cell viability and did not modified the amount of 
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the different downstream targets of Chk1 neither increased the amount of the phosphorylated 
form of H2A.X, with the exclusion of one sample (Fig.4E; 4F). The chemo-sensitizer ability of 
LY2606368 was then evaluated also on the primary leukemic cells. To assess that the primary 
cells isolated from 3 Philadelphia-positive ALL patients were treated for 24 hours with 
LY2606368 (200 nM) in combination with the TKI, imatinib (5 M). The concomitant treatment 
showed an additive effect in term of reduction of the cell viability in comparison with the effect 
of the single treatment (Fig.4C). Finally to correlate the reduction of the cell viability with the 
induction of DNA damage, a Western blot analysis was performed on the primary cells of one 
Philadelphia-positive ALL patient. Although the amount of phospho-Chk1ser317 was not 
significantly higher in the sample treated with the two drug in comparison to the single 
treatments, the amount of H2A.X was synergistically increased (Fig. 4D).  
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Figure 4: Effect of LY2606368 on primary leukemic cells isolated from adult ALL patients and 
on peripheral mononuclear cells isolated from healthy donors. Cell viability analysis on 
primary leukemia cells isolated from 9 adult ALL patients treated with increasing concentration 
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of LY2606368 (100, 200 and 500 nM) for 24 hours.(A). The blot shows the induction of DNA 
damages on primary leukemic cells isolated from the peripheral blood of 4 newly diagnosed ALL 
patients treated for 24 hours with LY2606368 (100nM) (B). Cell viability assay of primary 
leukemia cells isolated from 3 Philadelphia-positive ALL patients treated with LY2606368 
(100nM) and imatinib (5 M) for 24 hours. The graph represents the main of response to the 
combination of the three patients (C).The blot shows the induction of DNA damages on primary 
leukemia cells isolated from a Philadelphia-positive patient after 24 hours of treatment with 
LY2606368 (100nM) in combination with imatinib (5M)(D). Cell viability assay of mononuclear 
cells isolated form the peripheral blood of 5 healthy donors, treated with increasing 
concentration of LY2606368 (100, 200 and 500 nM)(E). The blot shows the expression of 
different proteins of the Chk1 pathways after 24 hours of incubation with LY2606368 (100nM) 
on the mononuclear cells isolated from the peripheral blood of 5 healthy donors (D). In the 
Western blot analysis the homogeneity of the protein loaded (30 g) was determined by using 
an internal control (β-actin). 
 
Discussion 
Various studies have showed the effectiveness of different Chk1/Chk2 inhibitors as 
monotherapy or in combination with chemotherapy drugs or radiotherapy in different kind of 
tumors[72,141–146]. The biological hypothesis of these studies is that tumor cells can survive 
to therapy activating the DDR and delay the cell cycle progression to prevent lethal cell division 
[60]. Many compounds arrest tumor cells in different phases of the cell cycle. For instance, the 
purine nucleoside analogue clofarabine, arrests tumor cells in G1/S phase due to the inhibition 
of DNA synthesis [147]. As already mentioned, one of the most important regulator of the cell 
cycle is the Checkpoint kinase 1 (Chk1). In BCR/ABL1-positive cells the hyper activation of the 
ATR-Chk1 pathway after the exposure with different genotoxic agents has been associated with 
a delay in G2/M progression and thus with a possible mechanism of resistance to 
treatment[148]. Sarmento and colleagues found that T-ALL cells over-express Chk1 and then 
demonstrated that the aberrant expression is necessary for the proliferation and the survival of 
cancer cells[73]. In this study we demonstrated that Chk1 functionality is fundamental for the 
survival of B-/T-ALL cell lines and primary cells, and that the inhibition of this kinase using, 
LY2606368, sensitized both cell lines and primary cells to the cytotoxicity of different 
compound normally used for the treatment of adult B-/T-ALL patients. In line with our previous 
work on the efficacy of the PF-0477736 in single agent, the treatment with LY2606368 reduced 
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the cell viability in a time and dose-dependent manner in all the treated cell lines. The 
sensitivity to the compound was not correlated with the mutational status of p53, with the 
leukemia sub-type (Table 1) or with the basal expression of Chk1/Chk2 (Data not showed). The 
reduction of the cell viability was associated with the induction of cell death via apoptosis in all 
the treated cell lines, confirming the critical role of Chk1 in the proliferation and in the viability 
of ALL cells. To deeply investigate the consequence of Chk1 inhibition on cell cycle regulation 
and to clarify mechanisms of cell death, different cell lines were cell cycle and Western blots 
analyses were performed. The cell cycle analyses highlighted that in B-/T-ALL cell lines the 
compound reduced the amount of cells G2/M phase and increased the percentage of cells in 
G1/S and early S phase. The reduction of the G2/M phase together with reduction of the 
mitotic marker phospho-Histone H3 (pHH3ser10) excluded the mechanism of cell death through 
mitotic catastrophe and corroborated the hypothesis of King C. and colleagues[76] of the 
replication catastrophe. The single agent efficacy of LY2606368 showed on the cell lines were 
confirmed on different primary leukemic cells isolated from adult B-ALL patients. Although the 
compound deeply reduced the cell viability and increased the DNA damages in all the primary 
cell treated, we could not define any predictive factors of response. The idea of interfering with 
DNA damage response pathway in human cancer as a means to improve the cytotoxicity of 
DNA damaging therapies has been demonstrated in many pre-clinical studies. Here we 
evaluated the effectiveness of the LY2606368 as a chemo-sensitizer agent for the treatment of 
ALL. We showed that LY2606368 sensitized both Philadelphia-positive cell lines and primary 
leukemic cells to the toxic effect of the two TKIs, imatinib and dasatinib. The combinations 
(LY2606368+TKI) not only significantly reduced the cell viability in comparison to the effect of 
the single treatments but also increased the amount DNA damages (H2A.X), confirming the 
abrogation of the DNA damage response and the consequently accumulation of DNA damages. 
Similar results were found in Philadephia-negative cell lines, combining LY2606368 with the 2’-
deoxyadenosine analogue, clofarabine. Finally by assessing different schedules in the 
combination between LY2606368 and clofarabine, we demonstrate that the sequence on which 
the compounds were added to the media did not significantly modify the effect of the 
combination. We believe that the inhibition of Chk1/Chk2 by LY2606368 could be a promising 
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strategy to limit adverse events, by reducing the doses needed to reach a sufficient cytotoxic 
effect, and could increase the effectiveness of imatinib, dasatinib and clofarabine, by inhibiting 
the survival of cancer cells (Fig.5). 
 
 
Figure 5: Schematic representation of the effect of LY2606368 on leukemic blast after the 
exposure to different genotoxic agent. The left side of the cartoon hypothesizes how leukemic 
cell could survive to chemotherapy drugs and to other genotoxic agent, activating the cell cycle 
checkpoint and arresting the cell cycle progression. The right side of the cartoon hypothesizes 
the mechanism of action of the compound in enhancing cell death and inducing checkpoint 
override after the exposure to different DNA damaging agents. 
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Methods 
Leukemia cell lines and primary samples 
Human B- (BV-173, SUP-B15, REH, NALM-6, NALM-19) and T-ALL (MOLT-4, RPMI-8402, CCRF-
CEM) cell lines were obtained from Leibniz-Institut DSMZ-Deutsche Sammlung von 
Mikroorganismen und Zellkulturen GmbH (Germany). Cells were cultured in RPMI-1640 
medium (Invitrogen, Paisley, UK) with 1% l-glutamine (Sigma, St. Louis, MO), penicillin and 
streptomycin (Gibco, Paisley, UK) supplemented with 10%-20% fetal bovine serum (Gibco) in a 
humidified atmosphere of 5% CO2 at 37°C. Primary blast cells from 9 newly diagnosed 
Philadelphia-positive ALL cases were obtained, upon written informed consent, from the bone 
marrow and the peripheral blood by density gradient centrifugation over Lymphoprep 
(Nycomed UK, Birmingham). Mononuclear cells were isolated from the peripheral blood of5 
healthy donors. Online databases have been interrogated to molecularly characterize leukemia 
cell lines: International Agency for Research on Cancer (IARC) TP53 database (http://www-
p53.iarc.fr/) and the Catalogue of Somatic Mutations in Cancer, (COSMIC, http:// 
http://www.sanger.ac.uk/genetics/CGP/cosmic/). 
 
Drugs and Reagents 
The Chk1/Chk2 inhibitor LY2606368 was provided by Lilly Oncology. The purine nucleoside 
antimetabolite (clofarabine) and the tyrosine kinase inhibitors (imatinib and dasatinib) were 
bought by Sigma-Aldrich web site.  
Cell viability assay 
To evaluate the cytotoxic effect of the treatment with LY2606368, B- and T-All precursor 
leukemia cell lines were seeded in 96-well plates at 50,000 cell/100 μl/well with increasing 
concentrations of drug (1-100 nM ) for 24 and 48 and incubated at 37°C. Cell viability was 
assessed by adding WST-1 reagent (Roche Applied Science, Basel, Switzerland) to the culture 
medium at 1:10 dilution. Cells were incubated at 37°C and the optical density was measured by 
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microplate ELISA reader at λ450 after 3 hours. The amount of the formazan formed directly 
correlates to the number of metabolically active cells. All viability experiments were performed 
in triplicates and repeated in least two separated experiments. 
Primary leukemic cells viability assay 
To assess the effect of LY2606368 on primary leukemic blasts, the cells from 9 newly diagnosed 
Philadelphia-positive and Philadelphia-negative ALL cases were obtained, upon written 
informed consent, from the peripheral and bone marrow blood samples by density gradient 
centrifugation over Lymphoprep (Nycomed UK, Birmingham).Primary cells were seeded on a 6 
well plates at 500.000 cells/ml and incubated with increasing concentration of LY2606368 for 
24 hours at 37°C. In ex-vivo primary leukemia cells the effects on cell viability was assessed by 
counting viable and non-viable cell numbers by the Trypan blue dye exclusion method. 
Combination index assay 
In order to evaluate the effectiveness of LY2606368 as chemo-sensitizer agents, B-/T-ALL cell 
lines were seeded in 96-well plastes at 50,000 cell/100μl/well with increasing concentration of 
the compound (dilution rate 1:2) and increasing concentration of a second drug (dilution rate 
1:2), for 24 and 48 hours at 37°C. Cell viability was assessed using WST-1 (Roche Applied 
Science, Basel, Switzerland). Cells were incubated at 37°C and the optical density was measured 
by microplate ELISA reader at λ450 after 3 hours. The amount of the formazan formed directly 
correlates to the number of metabolically active cells. All viability experiments were performed 
in triplicates and repeated in least two separated experiments. 
Annexin V staining of apoptotic cells 
To assess the effect of the compound in the induction of apoptosis, three different increasing 
concentrations of LY2606368 were used to treat cells lines in order to detect apoptotic, necrotic 
and cell debris. Cell lines were seeded in 12-well plates at 500,000 cell/1 ml with increasing 
concentrations of drug (NALM-6, NALM-19, MOLT-4 and CCRF-CEM: 7.5, 15 and 30 nM; BV-173 
and RPMI8402: 2, 7.5 and 15 nM; SUP-B15 and REH: 50, 100 and 200 nM) for 24 and 48 hours 
and incubated at 37°C. Following the treatment, cells were harvested and stained with Annexin 
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V/Propidium Iodide (PI) according to the manufacturer's instruction (Roche). The percentage of 
Annexin V-PI positive cells was determined within 1 × 104 cells of the population by flow 
cytometry (Facs CantoII, BD Biosciences Pharmingen, San Jose, California, USA). The mean 
percentage of Annexin V-PI positive cells and standard error measurement was calculated from 
at least two separate experiments. 
Western Blot analysis 
All cell lines were plated in 6-well plates at 500,000 cell/1 ml with increasing concentrations of 
drug for different time points and incubated at 37°C. For evaluate the effect of combination of 
the Chk inhibitor with other drugs (imatinib, dasatinib and clofarabine) were used as dosage the 
IC50 for the single drug after 24 hours of treatment. The drugs in the combination were added 
simultaneously. At the end of the treatment, the cells were collected and lysate using a specific 
buffer made of KH2PO4 0,1 M (pH 7,5), Igepal 1% (NP-40), β-glicerofosfato 0,1 mM and 
complete protease inhibitor cocktail 1X (Roche Diagnostics).For each sample 30-50ug of protein 
were fractioned on Mini-Protean TGX stain-free precasted gels, blotted to nitrocellulose 
membranes (Bio-Rad Trans-blot turbo transfer pack) and incubated overnight with the 
following antibodies: Chk1 (#2345S), phosphorylated Chk1 (Ser317)(#2344S), phosphorylated 
Chk1(Ser296)(#2349S) and Chk1 (Ser345)(#2348S), Cdc25c (#4688S), phosphorylated Cdc25C 
(Ser216)(#9528S), Cdc25a (#3652), Cdc2 (#9112S), phosphorylated Cdc2 (Tyr15)(#4539S), 
phosphorylated H2A.X (Ser139) (γ-H2A.X) (#2577S), Caspase3 (#9662S), Parp 
(#9542S),phosphorylated Histone 3 (Ser10) from Cell Signaling. Antibody for CDK2 (Cdc1)(sc-
163) came from Santa Cruz biotechnology. Antibody to β-actin came from Sigma (St. Louis, 
MO). Finally all these antibodies were detected using the enhanced chemiluminescence kit ECL 
(GE) and the compact darkroom ChemiDoc-It (UVP).  
Cell Cycle analysis  
The cell lines were seeded in a 24 wells plate at the concentration of 500,000 cells/1 ml and 
treated for 6 and 24 hours at 37°C. After the right incubation time the cells were harvested and 
washed with cold PBS. After the wash the PBS was discarded and the cell were fixed using 
ethanol 70% and stored at -20°C for 24 hours. After the fixation period the ethanol was 
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removed by one wash in PBS and the cells were incubated for 30 minutes at 37°C with the 
staining mix ( sodium citrate pH 2.5 100mM, propidium iodide 2.5mg/ml, RNAse 10mg/ml and 
dH2O). The cell cycle analysis was conducted using the BD FACS Canto and the quantitative 
analysis using Modfit LT software (Verity). 
Phospho-histone H3/Propidium Iodide co-staining  
To evaluate the expression of phospho-Histone H3 (marker of mitosis) different cell lines were 
treated with LY2606368 (IC50 after 24 hours). The cell lines were seeded at the concentration 
of 500,000 cell/ml and treated for 18, 24, 30 and 48 hours at 37°C. After the right period of 
incubation the cell were harvested, washed twice in ice cold PBS and fixed in -20°C with 70% 
ETOH for 24 hours. After the right fixation period the cells were washed twice with 
PBS+0.5%Tween 20 and with PBS+0.1% BSA. The cells were incubated in darkness with FITC-
conjugated Phospho-HH3 antibody, dilution rate 1:100 in PBS+0.1%BSA, for 1 hour on ice 
(Phospho-Histone H3 (ser10) Antibody Alexa Fluor 488 conjugate #9708 Cell Signaling).To 
remove the exceeded of antibody the samples were washed twice in PBS and the fixed for 30 
minutes with -20°C 70%ETOH. After the second fixation the cells were washed twice in cold PBS 
and then stained with the staining mix(( sodium citrate pH 2.5 100mM, propidium iodide 
2.5mg/ml, RNAse 10mg/ml and dH2O) for 30 minutes at room temperature. The cell cycle 
analysis and the detection of the phosphor-HH3 positive cells were conducted using the BD 
FACS Canto and the quantitative analysis using Modfit LT software (Verity). 
Statistics 
All the differences in percentages of reduction of the cell viability were analyzed by unpaired t-
test (P≤0.05 was considered as statistically significant). 
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Table 1: Leukemia sub-type, karyotype, mutational status of p53 and IC50 value (after 24 
hours) of the panel of B-/T-ALL cell lines 
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Supplemental figure 1: Cell cycle profile of BV-173, NALM-6 and REH after 18, 24, 30 and 48 
hours of incubation with LY2606368 (IC50 value)(A). The blots show the expression of different 
proteins of the Chk1 pathway on BV-173, NALM-6 and REH cell lines after 18, 24, 30 and 48 
hours of incubation with LY2606368 (IC50 value)(B).Cell viability assay of NALM-6 and REH cell 
lines treated with LY2606368 and clofarabine using different schedules (C). Schematic 
representation of the number of cells positive for phospho-HH3 (ser10) antibody as marker of 
mitosis. NALM-6 and REH cell lines were incubated with or without LY2606368 (30 and 100 nM 
respectively) for 18, 24, 30 and 48 hours. In the graph the amount of positive cells for Phospho-
HH3(Ser10) are showed as a percentage of the total amount of cells (D). 
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Abstract 
Due to inadequate treatments, the survival rate of adult patients with acute lymphoblastic 
leukemia (ALL) is still very poor. Thus there is a need to improve the efficacy of conventional 
therapy and to discover novel specific targets for a more personalized therapy. In this study we 
evaluated the effectiveness of MK-1775, a selective Wee1 inhibitor, as single agent and in 
combination with different compounds conventionally used for the treatment of B-/T-ALL. The 
inhibition of Wee1 kinase drastically reduced the cell viability, modified the cell cycle profile 
and induced apoptosis in B-/T-ALL cell lines and on primary leukemic cells isolated from adult 
ALL patients. The chemo-sensitizer ability of the compound was then evaluated combining MK-
1775 with different compound normally used for the treatment of adult ALL patients. 
Interestingly, the treatment with MK-1775 strongly sensitized both cell lines and primary 
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samples to the toxic effect of different compounds and in particular to the tyrosine kinase 
inhibitor (TKis), bosutinib, to the purine nucleoside antimetabolite, clofarabine, and to the 
Chk1/Chk2 inhibitor PF-00477736. This manuscript highlights the in vitro/ex-vivo efficacy of 
MK-1775 for the treatment of ALL. 
Introduction 
Today different therapeutic approaches are available for the treatment of acute lymphoblastic 
leukemia (ALL). The identification of novel genetic alterations allowed to better classify ALL 
patients and to develop innovative therapies. Despite all the enormous progresses that have 
been made in the treatment of ALL, the cure rate, especially for adult patients, is still very low 
(less than 35%). The treatment of ALL adult patients, with the exclusion of compounds against 
particular oncogenes, is mainly associated with the use of chemotherapy [95,136,140,149]. 
Thus there is a need to increase the efficacy of current treatments in order to amplify the rate 
of cured patients and reduce the number of relapses. A successful strategy is to deeply 
understand the mechanisms by which leukemic cells respond and survive to therapies and, 
consequently, to inhibit them. Nowadays it is known that tumor and normal cells respond to 
DNA damages activating specific pathways in order to survive and in particular activating the 
DNA damage response (DDR) pathways. Although different molecular pathways are associated 
with the DDR, the main three involved in the maintenance of genome integrity and in the cell 
cycle regulation are the ataxia telangiectasia and Rad3-related protein (ATR)/ Checkpoint kinase 
1 (Chk1), the  ataxia telangiectasia mutated (ATM) /Checkpoint kinase 2 (Chk2) and the Wee1 
pathway[124,150]. These kinases are activated in the presence of DNA damages and prevent 
cell with altered DNA to move through the cell cycle and complete cell division. Different 
damaging agents, like IR ray, alkylanting agents, UV ray or oxygen radicals can generate DNA 
damages and trigger the ATR/Chk1, ATM/Chk2 and Wee1 response [127,33]. Chk1 and Chk2 
kinases are mainly involved in the regulation of S and G2 phase and in particular the first one is 
involved in the stabilization of the replicative forks and the homologous recombination repair. 
Wee1 is a checkpoint kinase, involved mainly in the regulation of G2/M transition through the 
inhibitory phosphorylation of both Cyclin-dependent kinase 1 (CDK1, Cdc2) and 2 (CDK2, 
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Cdc1)respectively [150].In the presence of DNA damages to prevent cell cycle progression both 
CDK1 and CDK2 are phosphorylated (Tyrosine 15 reside) thus avoid the generation of the 
CDK/cyclin complex and the progression of cell cycle [151]. The inhibitory phosphorylation of 
CDK1/CDK2 is directly catalyzed by Wee1 and simultaneously enforced by Chk1 which promote 
the degradation of both phosphatase CDC25A/C. WEE1 gene has been found over-expressed in 
different kind of solid tumor (glioblastoma, osteosarcoma, breast and colon cancer) especially 
in those with the tumor-suppressor p53 mutated [152–154]. Because of the biological function 
of Wee1 in cell cycle regulation, different Wee1 inhibitors (PD0166285, PD0407824 and MK-
1775) have been developed to improve the efficacy of DNA-damaging agent for the treatment 
of different cancers [143,155]. In hematological diseases the expression of Wee1 gene has been 
found higher in tumor samples when compared to the expression of normal peripheral 
mononuclear cells. Indeed Anderson and colleagues showed that the expression of Wee1 gene 
was significantly higher in B-/T-ALL leukemic blast isolated from different patients in 
comparison with the expression of healthy donor[156]. Based on this background in this study 
we sought to evaluate the effectiveness of the Wee1 inhibitor, MK-1775, as monotherapy and 
in combination with different drugs, like tyrosine kinase inhibitors (bosutinib authentic or 
bosutinib isomer), checkpoint kinase (Chk1/Chk2) inhibitors (PF-04477736) and antimetabolites 
drugs (clofarabine) for the treatment of B-/T-acute lymphoblastic leukemia.  
Results 
MK-1775 reduces the cell viability and triggers the apoptotic death in B-/T-(ALL) cell lines 
To evaluate the efficacy as single agent of the compound, a panel of 8 B-/T-ALL cell lines was 
treated for 24, 48 and 72 hours with increasing doses of the MK-1775 (from 6 to 5,000 nM, 
dilution rate 1:3) and the reduction of cell viability was evaluated using the colorimetric assay 
MTS. MK-1775 reduced the cell viability in dose and time-dependent manner in all cell lines. In 
particular, the most sensitive cell line after 24 hours of incubation was the Philadelphia-positive 
cell line, BV-173, with an IC50 of 500 nM, while the less sensitive one was the T-ALL cell line, 
CCRF-CEM, with an IC50 of 10 uM (Fig. 1A). In order to explain the high heterogeneity in term of 
response to the treatment, the basal expression of different proteins involved in the DDR 
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pathway (Wee1, phospho-Chk1ser317, Chk1, phospho-Chk2thr68, Chk2, phospho-Cdc2tyr15, Cdc2 
and -H2AX) was evaluated by Western blot. Despite each cell line showed a specific pattern of 
expression of the different key elements of the DDR, there was no correlation with the 
sensitivity to MK-1775 (Fig. 1B). Moreover similar to the results of our previous study 
evaluating the efficacy PF-0477736 on the same panel of cell lines, the sensitivity to the 
compound did not correlate with the leukemia subtypes, with the karyotype or with the 
mutational status of the tumor-suppressor p53 [133]. The reduction of the cell viability was 
then correlated with the activation of cell death via apoptosis. To this purpose different cell 
lines were incubated for 24 hours with increasing concentration of MK-1775, stained with 
Annexin V/Propidium Iodide (Pi) and then the amount of apoptotic cells was detected by 
cytofluorimetry. In all cell lines the inhibition of the Wee1 activated the apoptotic cell death in a 
dose-dependent manner (Fig. 1E). Then the activation of the apoptotic cascade was correlated 
with the induction of DNA damages by Western blots. Cells were incubated for 24 hours with 
MK-1775 (dose nearest to the IC50) and then stained for different antibodies. In the treated 
samples, the inhibition of Wee1 increased the amount of H2AX (marker of DNA damages) and 
of the cleaved isoform of Parp-1 (marker of apoptosis) (Fig. 1C). 
The inhibition of Wee1 perturbs the cell cycle profile and increases S and G2/M 
phases  
The biological consequences of Wee1 inhibition were then analyzed in term of perturbation of 
cell cycle progression. Different cell lines were treated for 24 hours with increasing 
concentration of MK-1775 and then stained with Pi. The treatment reduced the amount of the 
cells in G1 phase and progressively increased number of cells in S and in G2/M phase (Fig.1D). 
The modifications of the cell cycle profile induced by MK-1775 were correlated with the 
expression of different proteins involved in cell cycle regulation. The treatment reduced the 
level of expression of both Cdc2 and phospho-Cdc2Tyr 15, confirming that the catalytic activity of 
Wee1 was disrupted. Then in order to evaluate the effect of the compound on the checkpoint 
kinase 1 functionality, the level of expression of phospho-Chk1ser317(marker of ATR-dependent 
activation of the DDR pathway,), phospho-Chk1ser296(auto-phosphorylation site and marker of 
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Chk1 functionality) and of the basal form of Chk1 was evaluated in each cell lines. The 
expression of phospho-Chk1 ser296 was very heterogeneous among the different cell lines while 
the level of expression of phospho-Chk1ser317 was increased, confirming the induction of DNA 
damage, in all the cell lines. To better understand the mechanism of action of the compound 
and to evaluate the hypothetic mechanism of death through the mitotic catastrophe, the 
expressions of the phospho-HH3ser10, markers of mitosis, was evaluated in all the cell lines after 
the treatment. In different cell lines (SUP-B15, NALM-6, NALM-19, MOLT-4 and RPMI-8402) the 
incubation with MK-1775 increased the phospho-HH3ser10, confirming the results found in the 
cell cycle analysis (Fig. 1E; 1D). Finally in order to evaluate the effect of the compound 
specifically on checkpoint G2/M, BV-173 and CCRF-CEM cell lines were incubated with 
increasing concentration of MK-1775 ( BV-173: 0.4 and 0.8 uM; CCRF-CEM: 5 and 10 uM) for 12 
hours and then the level of mRNA expression of different genes involved in the DNA damage 
response and in the regulation of G2/M checkpoint was analyzed using qPCR (Predesigned 96-
well panel for use with SYBR® Green, BioRAD). Different genes involved in cell cycle regulation 
and in the response to DNA damages were differentially expressed between control and 
treated samples. In particular in both the cell lines different genes involved in DNA damage 
response, G2/M transition and in the activation of the apoptosis (ATR, ATM, CDC25C, CDC25B, 
CDC2, CCNB1, CCNB2, GADD45A and GADD45B) were up-regulated in the treated samples in 
comparison to the control while genes involved in the negative regulation of the transition 
G2/M, like PKMYT1, were down-regulated. Interestingly the level of expression of Wee1 was 
only weakly reduced in both the cell lines (Fig. S1B). Using a specific threshold (2.5), in both the 
cell lines the expression of PKMYT1 was significantly reduced between treated and untreated 
cells. The significantly up-regulated genes were GADD45a in BV-173 cell lines and CCNB1/B2 in 
CCRF-CEM cell line (Fig.1E). 
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Figure 1: MK-1775 reduces cell viability, increase the apoptosis and deeply change the cell 
cycle profile in B-/T-ALL cell lines. A) IC50 values of B-/T-ALL cell lines after 24, 48 and 72 hours 
of incubation with MK-1775. The asterisk (*) in the legend of the graph represent the cell line 
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with the mutational status of the onco-suppressor p53.B) Apoptosis analysis of BV-173, NALM6, 
MOLT-4 and CCRF-CEM cell lines incubated with increasing concentration of MK-1775 (highest 
dose close to IC50 value, the other two doses are respectively 1/2 and 1/4 of the IC50) for 24 
hours. C) Cell cycle profile of BV-173,MOLT-4, CCRF-CEM and NALM-6cell lines incubated with 
decreasing concentration of MK-1775 (highest dose close to IC50 value, the other two doses are 
respectively 1/2 and 1/4 of the IC50) for 24 hours. D) In the blots B-/T-ALL cell lines were 
incubated for 24 hours with MK-1775 (IC50 value). The homogeneity of the protein loaded 
(40ug) was determined using an internal control (β-actin).E) Quantitative analysis of the 
expression of different elements of the G2/M checkpoint. BV-173 and CCRF-CEM were treated 
for 12 hours with increasing concentrations of the MK-1775 and then the total amount of RNA 
was extracted. In the blots the up-regulated genes are represented as red dots while the down-
regulated genes between treated samples and controls are represent as blue dots (threshold 
2.5) . 
 
MK-1775 reduces the cell viability of primary leukemic cells isolated from adult 
B-ALL patients 
The cytotoxicity of the compound was evaluated on primary leukemic blasts isolated from the 
bone marrow and peripheral bloods of adult ALL patients (n= 6) at diagnosis, and on normal 
mononuclear cells isolated from the peripheral blood of healthy donors (n=5). Cells were 
treated with increasing concentration of the compound (2.5, 5 and 10 uM) for 24 hours and 
then the reduction of the cell viability was assessed using Trypan blue exclusion dye. In line with 
the results found on the cell lines, the MK-1775 reduced the cell viability in a dose-dependent 
manner in all the primary samples treated (Fig.2A), however on the mononuclear cells the 
compound did not modified the cell viability (Fig. 2B). To evaluate the response of the primary 
leukemic cells in term of expression of different genes involved in the response to DNA 
damages, cells were incubated with increasing concentration of MK-1775 ( 2.5 and 5 uM) for 12 
hours and then qPCR were performed. Among all the different genes differentially expressed 
between control and treated samples, different fundamental genes for the checkpoint G2/M 
were significantly up-regulated (threshold 2.50): CCNB1, CDC25C, CDK1 (CDC2), WEE1 and 
GADD45B (Fig. 2C; S1B). The results of the gene expression analysis showed that the inhibition 
of Wee1 enhanced the expression of different genes involved in the transition from the G2 into 
M phase. To confirm these data and to evaluate the effect of MK-1775 on mitosis, the primary 
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leukemic cells isolated from one adult case with Philadelphia-negative B-ALL patient and the 
mononuclear cells isolated from the peripheral blood of one healthy donor were treated with 
MK-1775 (2.5, 5, 10 uM) for 24 hours and then stained with the Giemsa and May Grünwald 
solutions to discern the nuclei from the cytoplasm and to evaluate nuclei morphology. In the 
primary samples MK-1775 significantly altered the morphology of the nuclei, increasing the 
number of micro/macro nuclei and of DNA bridges among the nuclei. Interestingly all the 
alterations were restricted to leukemic samples, indeed in the mononuclear cells there was no 
difference in the morphology of the nuclei between control and treated cells (Fig. 2D). 
Conclusively the primary leukemic cells from an adult B-ALL patient were treated with 
increasing concentration of MK-1775 (2.5, 5 and 10 uM) for 24 hours and then stained for 
phospho-Chk1ser317, Chk1, phospho-Cdc2tyr15, Cdc2 and H2AX. Similar to the results found on 
the different cell lines, the compound deeply reduced the expression of both basal and 
phosphorylated isoforms of Cdc2 while increased the amount of phospho-Chk1 and H2AX, 
confirming at the same time the inhibition of Wee1 functionality and the induction of DNA 
damages 
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.  
Figure 2: MK-1775 abrogates the G2/M checkpoint in the primary cells isolated from adult 
ALL patients. A) Cell viability analysis of primary leukemic cells isolated from 6 adult B-ALL 
patients incubated for 24 hours with 2.5, 5 and 10 M of MK-1775. B) Cell viability analysis of 
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mononuclear cells isolated from the peripheral blood of 5 healthy donors incubated for 24 
hours with 2.5, 5 and 10 uM of MK-1775. C) Quantitative analysis of the expression of different 
elements of the G2/M checkpoint. Primary leukemic cells were treated for 12 hours with 
increasing concentrations of the MK-1775 (2.5 and 5 M) and then the total amount of RNA 
was extracted. In the blots the up-regulated genes are represent as red dots while the down-
regulated genes between treated samples and controls are represent as blue dots. D) Light 
microscopy analysis of primary leukemic cells and mononuclear cells incubated with increasing 
concentration of MK-1775 (2.5, 5, 10 uM) and then stained with the Giemsa and May Grünwald 
solutions to discern nuclear structure alterations. The black arrows indicate different DNA 
bridges, markers of aberrant mitosis. E) Western blot analysis of primary leukemic cells treated 
with MK-1775 (2.5, 5 and 10 uM) for 24 hours. The protein extracts were stained p-Chk1 
ser317, Chk1, p-Cdc2 tyr15, Cdc2 and H2AX ser139. The homogeneity of the protein loaded 
(70ug) was determined using an internal control (β-actin). 
 
MK-1775 sensitizes leukemia cell lines to the toxic effect of clofarabine.  
The efficacy as chemo sensitizer agent of MK-1775 have been showed in different studies, 
however none of them were focused on the different compounds normally used for the 
treatment of ALL[84,157]. Thus to evaluate the chemo-sensitizer efficacy of MK-1775 on ALL 
patient’s treatments different combinations have been made using compounds normally used 
in the clinic. In particular different Philadelphia-negative B-/T-ALL cell lines were treated for 24, 
48 and 72 hours with increasing concentration of MK-1775 (from 6 to 5000 nM, dilution rate 
1:3) in combination with the purine nucleoside analogue, clofarabine. Based on the sensitivity 
of each cell lines to clofarabine (data not showed), Nalm6, Nalm19 and REH cell lines were 
treated with 2.5, 5, 10 nM while CCRF-CEM, MOLT-4 and RPMI-8402 with 5, 10, 20 nM. The 
combination of the two compounds additively reduced the cell viability in comparison to the 
effect of the single treatments. The results of the combination index analysis showed that there 
was no difference in term of sensitivity among the different cell lines and in particular between 
p53 mutated and p53 wild type cell lines () (Fig. 3A). Based on the results of the combination 
index analyses, NALM-6, REH, CCRF-CEM and RPMI-8402 cell lines were treated with 
clofarabine (5nM) and MK-1775 (180 nM) for 24 hours and then stained with Pi. The 
combination did not significantly alter the cell cycle profiles in comparison with the effects of 
the single treatments (Fig. 3B). To correlate the effect in term of reduction of the cell viability 
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with the activation of cell death, two cell lines, MOLT-4 and NALM-6, were treated with MK-
1775 (185nM) in combination with clofarabine ( MOLT-4 20nM and NALM-6 10 nM) and then 
the amount of apoptotic cells was detect using cytofluorimetry. In both the cell lines the 
combination of the two compounds increased significantly the amount of apoptoic cells in 
comparison to the effect of the single treatments. Despite results of the combination index 
analysis, in term of induction of apoptosis the p53 mutated cell lines resulted more sensible to 
the pro-apoptotic effect of the combination (Fig. 3C). Finally the effect of the combination was 
evaluated in term of reduction of the proliferation. To this purpose REH, NALM-6, MOLT-4 and 
CCRF-CEM cell lines were incubated with MK-1775 (180nM) and with sub-toxic concentration of 
clofarabine (respectively: 2.5, 5, 10 and 20 nM) for 6 days and the number of proliferating cells 
was assessed every 24 hours using Trypan Blue exclusion dye. In all the treated cell lines the 
combination of the two compounds drastically reduced the number of proliferating cells in 
comparison to the effect of the single treatments (Fig.3D). The effect of the combination 
between MK-1775 and clofarabine was then assessed on primary leukemic cells isolated form 
the peripheral blood and the bone marrow of 8 adult ALL patients. Primary cells were incubated 
with MK-1775 (5uM) and with increasing concentration of clofarabine (100, 250 and 500 nM) 
for 24 hours and then the reduction of the cell viability was quantified using Trypan blue 
exclusion dye. Although with high heterogeneity, in all the primary samples the combination 
with the two compounds significantly reduced the cell viability in comparison with the effect of 
the single treatment (Fig. 3E).  
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Figure 3: MK-1775 sensitizes Philadelphia-negative cell lines and primary leukemic cells to the 
cytotoxic effect, clofarabine. A) NALM-6, NALM-19, REH, MOLT-4, CCRF-CEM and RPMI-8402 
cell lines were treated for 24, 48 and 72 hours with increasing concentration of Mk-1775( from 
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6 to 5000 nM) with increasing concentration of clofarabine. All the data present are the mean 
of two independent experiments B) Cell cycle analysis of NALM-6, REH, CCRF-CEM and RPMI-
8402 cell lines treated with MK-1775 in combination with clofarabine for 24 hours. C) Apoptosis 
analysis of NALM-6 and MOLT-4 cell lines treated for 24 with MK-1775 (185 nM) and 
clofarabine (NALM-6: 10nM; MOLT-4: 20nM). D) Proliferation index assay of NALM-6 and CCRF-
CEM cell lines incubated with MK-1775 (185 nM) and sub-toxic concentration of clofarabine 
(respectively 2.5 and 20 nM) for 6 days. The number of living cells was evaluated using the 
Trypan Blue exclusion dye analysis. All the data present are the mean of two independent 
experiments. E) Cell viability analysis of primary leukemic cells isolated from adult Philadelphia-
negative B-ALL patients (n=8) incubated with MK-1775 (5 uM) and increasing concentration of 
clofarabine (0.1, 0.2 and 0.5 uM) for 24 hours. The reduction of the cell viability was evaluated 
using the Trypan Blue exclusion dye analysis. 
 
The inhibition of Wee1/Chk1/Chk2 kinases drastically reduces the cell viability, 
triggers apoptosis and modifies cell cycle profile in B-/T-ALL cell lines  
Due to the central role of both Wee1 and Chk1 kinase in cell cycle regulation the effect of the 
concomitant inhibition of these two kinases was evaluated in B-/T-ALL cell lines. The sensitivity 
of each cell lines to the Chk1/Chk2 inhibitors,PF-047736, have been recently published[133]. 
Thus the most sensitive and the less sensitive cell lines, RPMI-8402 and NALM-6, were chosen 
to evaluate the effect of the combination with MK-1775. To this purpose cells were treated 
with increasing concentration of MK-1775 (form 6 to 5000 nM, dilution rate 1:2) and decreasing 
doses of PF-0477736 (respectively 100, 50,25, 10 and 1000, 500, 250, 100 nM) for 24, 48 and 72 
hours. In line with the literature the inhibition of both Chk1 and Wee1 additively reduced the 
cell viability in both the cell lines[158]. Similar to what found in the co-treatment with 
Clofarabine, the cytotoxic effect of the combination of the two inhibitors was time and dose-
dependent (Fig.4A). To better understand the consequences of the inhibition of both Chk1 and 
Wee1 on the cell cycle profile, RPMI-8402 and NALM-6 cell lines were treated for 24 hours with 
MK-1775 (180 nM) and PF-0477736 ( respectively 25 and 250 nM) and then stained with Pi. In 
both cell lines the co-treatment increased the amounts of cells in S phase (Fig.4B). The effect of 
the inhibition of Chk1 and Wee1 on protein expression was evaluated using Western blot 
analysis. RPMI-8402 and NALM-6 were treated for 24 hours with MK-1775 and PF-0477736 and 
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then stained for the expression of phospho-Chk1 (ser345 and ser317), Chk1, phospho-Cdc2 
(Tyr15), Cdc2, phospho-HH3 (ser10), H2AX, pro caspase-3, Parp-1, and -Actin. In agreement 
with the results of the viability, the combination of the two compound synergistically increased 
the expression of H2AX, confirming the induction of DNA damages, and decreased the 
expression of phospho-Cdc2, confirming the inhibition of both Wee1 and Chk1 (Fig.4C). The 
effect of the double treatment was then evaluated in term of inhibition of cell proliferation. 
RPMI-8402 and NALM-6 cell lines were treated with MK-1775 (180 nM) and PF-0477736 
(respectively 25 and 250 nM) for 6 days and then the amount of cells was evaluated every 24 
hours. In both the cell lines the inhibition of both Wee1 and Chk1 completely reduce the 
proliferation rate, while the mono-treatment reduced the cell viability but only in the earliest 
time points (Fig.4D). The effect of the combination was then evaluated on primary leukemic 
cells isolated from 2 adult ALL patients. To this purpose primary cells were incubated for 24 
hours with MK-1775 (1000 nM) in combination with PF-0477736 (1000nM) and then the 
reduction of the cell viability was evaluated using Trypan blue exclusion dye. These experiments 
confirmed the results of the reduction of the cell viability found on the cell lines (Fig.4E). 
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Figure 4: The inhibition of Wee1 and Chk1/Chk2 kinases deeply reduced the cell viability, 
changed the cell cycle profile and inhibited the proliferation in B-/T-ALL cell lines. A) Cell 
viability assay of RPMI-8402 and NALM-6 cell lines treated for 48 and 72 hours with increasing 
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concentration of Mk-1775( 6nM-5 uM) with increasing concentration of PF-00477736 (RPMI-
8402: 10, 25, 50 and 100 nM; NALM-6: 250, 500, 1000 and 1500nM). All the data present are 
the mean of two independent experiments B) Cell cycle analysis RPMI-8402 and NALM-6 cell 
lines treated with MK-1775 in combination with PF-00477736 for 24 hours. C) Western blot 
analysis of RPMI-8402 and NALM-6 treated with MK-1775 and PF-00477736 for 24 hours. The 
protein extracts were stained p-Chk1ser317 p-Chk1ser345, Chk1, p-Cdc2tyr15, Cdc2, p-HH3 
(ser10) and H2AX (ser139). The homogeneity of the protein loaded (40ug) was determined 
using an internal control (β-actin). D) Proliferation index assay of RPMI-8402 and NALM-6 cell 
lines incubated with MK-1775 (185 nM) and sub-toxic concentration of PF-00477736 
(respectively 2.5, 5 and 20 nM) for 6 days. The number of living cells was evaluated using the 
Trypan Blue exclusion dye analysis. All the data present are the mean of two independent 
experiments. E) Cell viability analysis of primary leukemic cells isolated from adult B-ALL 
patients (n=2) incubated with MK-1775 (1 uM) and with PF-0477736 (1uM) for 24 hours. The 
reduction of the cell viability was evaluated using the Trypan Blue exclusion dye analysis. 
 
MK-1775 sensitizes leukemic cell lines to the tyrosine kinase inhibitor bosutinb 
The chemo-sensitizer activity of MK-1775 was also evaluated combining the Wee1 inhibitor 
with different tyrosine kinase inhibitors (TKIs), which represents the frontline therapy for the 
treatment of Philadelphia-positive acute lymphoblastic and chronic myeloid leukemia patients 
[159–162]. In particular the MK-1775 was combined with two isomers of the TKIs, bosutinib 
(here hence named as Bos, the authentic isoform, and Bos-I, a specific bosutinib isomer), which 
differ in term of specificity and of chemical proprieties [143,163]. We have already shown that 
Bos-I on PANC-1 cells has an off target inhibitory activity on Wee-1 and Chk1 kinases and also 
that this compound can sensitize tumor cells to gemcitabine [143]. The efficacy of the two 
isomers, in combination with MK-1775, was evaluated in term of reduction of the cell viability, 
activation of the apoptosis, and modification of protein expression on ALL cell lines and on 
primary cells. To assess the cytotoxicity as single agent of the two isomers, cells were incubated 
for 24, 48 and 72 hours with increasing concentration of Bos/Bos-I (from 6 nM to 5000 nM, 
dilution rate 1:3) and then the reduction of the cell viability was quantified using MTS reagent. 
The treatment with Bos reduced the cell viability not only of Philadelphia-positive cell lines (BV-
173 and SUP-B15), harboring the BCR-ABL1 fusion transcript, but also of different Philadelphia-
negative cells lines, due to the inhibitory effect on Src family kinases. Then efficacy of the Bos-I 
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was evaluated as single agent on both Philadelphia positive and negative cell lines. In 
Philadelphia positive cell lines the efficacy of the two isomers was almost the same but in  
Philadelphia negative cell lines the Bos-I significantly reduced the cell viability in comparison to 
the effect of the authentic isoform (Fig. 5A). In order to evaluate the efficacy of the two isomers 
in combination with MK-1775, different combination index assays were performed. The result 
of the analysis showed that the combination between Bos/Bos-I and MK-1775 additively 
reduced the cell viability of Philadelphia positive cell lines with no significant differences, in 
term of efficacy, between the two isomers. On contrary in the Philadelphia-negative cell lines 
there was a significant difference in term of effectiveness of the two combinations (Fig. 5B). In 
order to evaluate the effect of the combination on the induction of apoptosis, BV-173, SUP-B15, 
REH, NALM-6 and MOLT-4 were treated for 24, 48 and 72 hours with MK-1775 (180 nM) and 
sub-toxic concentration of Bos/Bos-I (BV-173 50nM; SUP-B15 100nM; REH,NALM-6,MOLT-4 
1uM). The greater effect in the induction of the apoptosis was seen after 72 hours of incubation 
with the two drugs. In the two Philadelphia-positive cell lines, BV-173 and SUP-B15, the 
treatment with MK-1775 and Bos significantly increased the number of apoptotic cells in 
comparison with the effect of the single treatments and to the effect combination between MK-
1775 and Bos-I. On the Philadelphia-negative cell lines the simultaneous treatment with MK-
1775 and Bos-I induced a significant increment of necrotic cells in comparison to the effect of 
effect of the single treatments and to the combination between MK-1775 and Bos (Fig.5C). To 
assess the effect of the combination of cell proliferation BV-173 and NALM-6 cell lines were 
incubated with sub-toxic concentration of MK-1775 (185 nM) and Bos/Bos-I (BV-173 50 nM; 
NALM-6 2uM) for 6 days and the amount of proliferating cells was evaluated every 24 hours. In 
line with the previous results on BV-173 the strongest effect in the inhibition of the 
proliferation was seen in the combination between MK-1775 and the authentic isomer of 
Bosutinib(Bos).Moreover in the combination between MK-1775 and Bos-I, no significant 
different were seen in the samples treated with MK-1775 alone or in addiction with Bos-I. 
Interestingly in the experiment with NALM-6 the effects of the two combinations were exactly 
the opposite of BV-173 cell line (Fig. 5D). Finally the efficacy of the combination between MK-
1775 and Bos/Bos-I was evaluated on primary cells isolated form the bone marrow and the 
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peripheral blood of 2 B-ALL patients. In the first experiment the primary cells isolated form a 
Philadephia-positive B-ALL patient were incubated with MK-1775 (5uM) and Bos (2uM) for 24 
hours and the the reduction of the cell viability was quantified using Trypan Blue. The results 
showed that the MK-1775 sensitized the primary cells to the effect of TKI, confirming the 
results on the Philadelphia-positive cell lines (Fig. 5E). Then the effect of MK-1775 in 
combination with Bos/Bos-I was evaluated on the primary cells isolated from a Philadelphia-
negative patient. Cells were incubated with MK-1775 (5uM) and Bos/Bos-I (2 uM) for 24 hours 
and then the reduction of the cell viability was quantified. The results of the experiment 
showed that also on Philadelphia-negative primary cells Bos-I, but not the authentic isomer of 
bosutin, increased the efficacy of MK-1775 in the reduction of the cell viability(Fig.5F). 
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Figure 5: MK-1775 increased the cytotoxicity of both Bos and Bos-I isomers but with 
differences between Philadelphia-positive and negative cell lines. A) IC50 values of B-/T-ALL 
cell lines after 24 hours of incubation with Bos (white column) and Bos-I (black column). All the 
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data presented are the mean of three independent experiments. All the data presented are the 
mean of two independent experiments. B) Cell viability assay of NALM-6, CCRF-CEM and MOLT-
4  cell lines treated for 72 hours with increasing concentration of Mk-1775( 6nM-5 uM) with 
increasing concentration of Bos/ Bos-I (250, 500 and 1000nM). All the data present are the 
mean of two independent experiments. C) Apoptosis analysis of SUP-B15 and NALM-6 cell lines 
incubated with MK-1775 and subtoxic concentration of Bos/Bos-I incubated for 72 hours. All 
the data present are the mean of two independent experiments. D) Proliferation index assay of 
BV-173 and NALM-6 cell lines incubated with MK-1775 (185 nM) and sub-toxic concentration of 
Bos/Bos-I (BV-173 50nM, NALM-6 2uM) for 6 days. The number of living cells was evaluated 
using the Trypan Blue exclusion dye analysis. All the data present are the mean of two 
independent experiments. E) Cell viability analysis of primary leukemic cells isolated from adult 
Philadelphia-positive B-ALL patient incubated with MK-1775 (5 uM) and with Bos (2uM) for 24 
hours. The reduction of the cell viability was evaluated using the Trypan Blue exclusion dye 
analysis. F) Cell viability analysis of primary leukemic cells isolated from adult Philadelphia-
negative B-ALL patient incubated with MK-1775 (5 uM) and with Bos/Bos-I (2uM) for 24 hours. 
The reduction of the cell viability was evaluated using the Trypan Blue exclusion dye analysis. 
 
Discussion 
The inhibition of the DNA damage response (DDR) is a promising strategy to sensitize tumor 
cells to the cytotoxicity of different compound by inhibiting the mechanisms that tumor cells 
up-regulates to repair DNA damages and to survive The DDR pathway plays a central role in the 
response to genotoxic drugs by activating the mechanism of DNA repair and by regulating cell 
cycle progression The efficacy of different inhibitors of the DDR has been well established in 
vitro and in vivo studies especially in solid tumors. Nowadays only few studies have been done 
to evaluate the effectiveness of DDR inhibitors in hematological malignacenes[105]. Recently 
Iacubucci and colleagues have showed the efficacy of PF-00477736, a potent Chk1/Chk2 
inhibitor, in single agent on ALL cell lines and primary samples[133]. Here we evaluated the 
efficacy of MK-1775 a specific Wee1 kinase inhibitor, as single agent and in combination with 
different compound on B-/T-ALL cell lines and on primary samples. Similar to the results found 
in the PF-0477736 study the inhibition of a central kinase involved in cell cycle regulation, like 
Wee1, mined the survival of leukemic cells. The compound deeply reduced the cell viability in 
all the treated cell lines and on different primary samples. The sensitivity to the compound was 
not related to the sup-type of leukemia, nether with the mutational status of the tumor-
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suppressor p53 nor with the basal expression of the Wee1 protein. The effect of the compound 
in single agent was not limited to the cell viability, but also inducted cell death via apoptosis 
and deeply modified the cell cycle profile. The cytotoxic effect of MK-1775 was then confirmed 
on different primary cells isolated from the bone marrow and the peripheral blood of adult B-
ALL patients. Interestingly the toxicity seen on the primary leukemic cells was not found on 
peripheral mononuclear cells isolated from the peripheral blood of healthy donors. The 
Western blots analysis highlighted the functional consequences of Wee1 inhibition. The on-
target efficacy of the compound was confirmed by the reduction of the phosphorylated form of 
Cdc2, direct target of Wee1. The treatment with the compound even in single agent increased 
the DNA damages (H2AX) and triggered the apoptotic death (Parp-1 cleavage) in all the cell 
lines treated. The increment of DNA damage was also confirmed by the increment of phospho-
Chk1 (ser317), confirming that the inhibition of Wee1 increased the intrinsic genetic instability. 
Interestingly in different cell lines (NALM-19, MOLT-4, CCRF-CEM and RPMI-8402) the 
treatment with MK-1775 reduced the protein level of phospho-Chk1 (ser296), site of auto-
phosphorylation and marker of Chk1 functionality, raising the hypothesis that the compound 
had an off target effect on Chk1. MK-1775 deeply modified the gene expression (Q-PCR 
analysis) of different elements of the G2/M checkpoint. The genes more significantly up-
regulated were GADD45A, involved in the activation of the apoptosis, and the cyclin B1/B2, 
fundamental for G2/M transition. Moreover in all the cell lines the treatment down-regulated 
the expression of PKMYT1, one of the main repressor of G2/M transition. These data confirmed 
the abrogation of the G2/M checkpoint by MK-1775. Similar results were obtained on the 
primary leukemic cells isolated from the bone marrow of an adult B-ALL patient. Using the 
same value of threshold seven genes were significantly up-regulated between treated samples 
and controls. All the above mentioned genes were involved in the transition through the G2/M 
checkpoint, confirming also on the primary cells the override of the G2/M checkpoint. The 
consequence of Wee1 inhibition in term of chemo-sensitization was then evaluated on 
leukemia cell lines and on primary samples. In order to evaluate if the inhibition of a key 
element of the DDR could sensitize leukemic cells to different therapies, cells were treated with 
MK-1775 in combination with different class of antineoplastic agents like tyrosine kinase 
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inhibitors, purine nucleoside analogue and Chk1/Chk2 inhibitor. The results of these 
experiments on the cell viability suggested that MK-1775 deeply sensitized the different cell 
lines to the toxic effect of the different compounds. Moreover similar results were seen in 
different experiments evaluating the effect to the combinations in the induction of the 
apoptosis and in the inhibition of the cell proliferation. These results were then confirmed on 
primary cells isolated form Philadelphia-positive and negative ALL patients. Finally the results of 
different experiments using the two isomer of the TKI, bosutinib, confirmed an off–target effect 
of Bos-I on Philadelphia-negative cell lines and primary samples. 
Materials and Methods  
Drugs and Compounds 
MK-1775 was purchased from MedChemexpress (http://www.medchemexpress.com). 
Clofarabine and PF-0477736 were obtained from Sigma (http://www.sigmaaldrich.com/). 
Bosutinib isomer (BOS-I) was purchased from LC Labs (http://www.lclabs.com/) while the 
authentic isoform (BOS) from Tocris (http://www.tocris.com/). 
Leukemia cell lines 
Human B- (BV-173, SUP-B15, REH, NALM-6, NALM-19) and T-ALL (MOLT-4, RPMI-8402, CCRF-
CEM) cell lines were cultured in RPMI-1640 medium (Invitrogen, Paisley, UK) with 1% l-
glutamine (Sigma, St. Louis, MO), penicillin and streptomycin (Gibco, Paisley, UK) supplemented 
with 10%-20% fetal bovine serum (Gibco) in a humidified atmosphere of 5% CO2 at 37°C. All the 
cell lines were purchased from Leibniz-Institut DSMZ-Deutsche Sammlung von 
Mikroorganismen und Zellkulturen GmbH (Germany). Cells Online databases have been 
interrogated to molecularly characterize leukemia cell lines: International Agency for Research 
on Cancer (IARC) TP53 database (http://www-p53.iarc.fr/) and the Catalogue of Somatic 
Mutations in Cancer, (COSMIC, http:// http://www.sanger.ac.uk/genetics/CGP/cosmic/).  
Primary leukemic cells 
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To assess the effect of MK-1775 on primary leukemic cells, samples from 8 B-ALL cases were 
obtained, upon written informed consent, from the peripheral and bone marrow blood by 
density gradient centrifugation over Lymphoprep (Nycomed UK, Birmingham) and then treated 
with the compound in single agent and in combination with different compounds. Primary cells 
were seeded on a 6 well plates at 500.000 cells/ml and incubated with increasing concentration 
of MK-1775 (2.5, 5 and 10 uM) for 24 hours at 37°C. For the combination studies cells were 
incubated with increasing concentration of the MK-1775 and with increasing concentration of 
clofarabine (100, 250 and 500 nM), PF-0477736 (1uM) or with Bos/Bos-I (1 and 2 uM) for 24 
hours at 37°C. In order to evaluate the cytotoxicity of the compound on peripheral 
mononuclear cells (PBMCs), cells isolated from the peripheral blood of 5 healthy donors, upon 
written informed consent, were treated with increasing concentration of MK-1775 (2.5, 5 and 
10 uM ). In ex vivo analysis the effect of the compound on the cell viability was detected by 
counting viable and non-viable cell numbers by the Trypan blue dye exclusion method (Sigma). 
Blast morphology and DNA bridge detection assay 
In order to evaluate macroscopic modification of cell morphology the primary cells isolated 
from the bone marrow a B-ALL patient and the mononuclear cells isolated from the peripheral 
blood of a healthy donor were seeded on a 6 well plates at 500.000 cells/ml and incubated with 
increasing concentration of MK-1775 (2.5, 5 and 10 uM) for 24 hours at 37°C. Cell were 
prepared for microscopy analysis spinning down on glass slips, using cytospin centrifuge, and 
then to discern the nuclei from the cytoplasm and to evaluate nuclei morphology were stained 
with the Giemsa and May Grünwald solutions. The slides were analyzed using an optical 
microscope and the pictures were taken using    software. 
Cell viability assay 
For screening the reduction of the cell viability we used the MTS assay (Promega). For the 
monotherapy studies cells were seeded into 96 well plates 0.5x106cells/ml and incubated at 37 
°C with different drugs for 24, 48 and 72 hours. For the combination index assay the two drugs 
in combination were added simultaneously and the cells were incubated for 24, 48 and 72 
hours. Cell viability was then determined by measuring the absorbance at 490nm. All data 
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points were normalized to untreated cells. All treatments were performed in triplicate and 
performed a minimum of 3 times. 
Cell proliferation assay 
To assess the inhibitory effect of the compound on the proliferation, cells were treated with 
MK-1775 in single agent or in combination with different compounds. Cells were seeded in 6 
well plates in a concentration of 0.2x106 cells/ml and incubated at 37 °C with MK-1775 for six 
days and the number of proliferating cells was evaluated every 24 hours using Trypan blue dye 
exclusion method (Sigma). All experiments were performed in triplicates and replicated a 
minimum of 2 times. 
Western Blot analysis 
To understand the biological and functional consequences of the inhibition of Wee1, Western 
blot analysis were performed. Cells were seeded in 6-well/plates at 0.5x106 cell/ml with 
increasing concentrations of MK-1775. After the appropriate time of incubation, proteins were 
extracted and then stained for different antibodies. In order to evaluate the effect of MK-1775 
in combination with other drugs (Bos/Bos-I, PF0477736 and clofarabine) cells were incubated 
for different time points and with specific concentration of drug. The drugs in the combination 
were added simultaneously. After the end of the treatment, the cells were collected and lysate 
using a specific buffer made of KH2PO4 0,1 M (pH 7,5), Igepal 1% (NP-40), β-glicerofosfato 0,1 
mM and complete protease inhibitor cocktail 1X (Roche Diagnostics).For each sample 50ug of 
protein were fractioned on Mini-Protean TGX stain-free precasted gels, blotted to nitrocellulose 
membranes (Bio-Rad Trans-blot turbo transfer pack) and incubated overnight with the 
following antibodies: Chk1 (#2345S), phosphorylated Chk1 (Ser317)(#2344S),Chk1 
(Ser345)(#2348S) and Chk1 (ser296)(#), Cdc2 (#9112S), phosphorylated Cdc2 (Tyr15)(#4539S), 
phosphorylated H2A.X (Ser139) (γ-H2A.X) (#2577S), Caspase3 (#9662S), Parp-1 
(#9542S),phosphorylated Histone 3 (Ser10) from Cell Signaling. Antibody to β-actin came from 
Sigma (St. Louis, MO). Finally all these antibodies were detected using the enhanced 
chemiluminescence kit ECL (GE) and the compact darkroom ChemiDoc-It (UVP).  
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Cell Cycle analysis  
In order to evaluate the effect of Wee1 inhibition in the cell cycle progression, different cell 
lines were treated with increasing concentrations of MK-1775 and for different time points. In 
the combination studies the drugs were added simultaneously. The cell lines were seeded in a 
24 wells/plate at the concentration of 0.5x106 and treated 24 or 48 hours at 37°C. After the 
right incubation time the cells were harvested and washed with cold PBS. After the wash the 
PBS was discarded and the cell were fixed using ethanol 70% and stored at -20°C for 24 hours. 
After the fixation period the ethanol was removed by one wash in PBS and the cells were 
incubated for 30 minutes at 37°C with the staining mix ( sodium citrate pH 2.5 100mM, 
propidium iodide 2.5mg/ml, RNAse 10mg/ml and dH2O).The cell cycle analysis was conducted 
using the BD FACS Canto and the quantitative analysis using Flowjo, Flowing and . 
Quantitative PCR 
To evaluate the effect of MK-1775 on the expression of different elements of the G2/M 
checkpoint, different cell lines (BV-173 and CCRF-CEM) and primary cells were treated for 12 
hours with increasing concentration of MK-1775. After the right amount of time cells were 
harvested and the total RNA was extracted using Maxwell simply RNA Blood kit (Promega) and 
1 ug of each RNA sample (quantified by ND1000 Spectophotometer) was reverse transcribed 
using  iScript Advanced cDNA Synthesys kit for RT-qPCR (Bio-Rad). For quantification of 
different elements of G2/M Checkpoint transcript levels, the commercial 96 wells PrimePCR 
plates (DNA damageDNA-ATM  ATR regulation of G2  M checkpoint, Bio-Rad) were employed 
according to the instructions of the manufacturer: Sso Advanced Universal Sybr Green 
Supermix (Bio-Rad) and LightCycler 480 System amplification protocol (Roche Diagnostics, 
Mannheim, Germany). For the normalization of the relative amount of mRNA, three differnent 
housekeeping genes were amplified (GAPDH, TBP and HPRT1). Data analysis was performed 
with PrimePCR analysis software (Bio-Rad). 
Statistical analysis 
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All the differences in percentages of reduction of the cell viability were analyzed by unpaired t-
test (P≤0.05 was considered as statistically significant). 
 
Supplementary Figure 1: A) Basal expression of Wee1, p-Chk1ser317, Chk1, p-Cdc2tyr15, Cdc2, 
H2AX in all the B-/T-ALL cell lines treated in this study. B) Graphic representation of the 
relative normalized expression of different genes involved in the ATR/ATM response to DNA 
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damages and to the regulation of the G2/M checkpoint. In the graph the expression of each 
gene in the treated samples is normalized to the expression of the controls.  
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Discussion 
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The present thesis aimed to evaluate the efficacy of the inhibition of the checkpoint kinase 
pathway as a novel strategy for the treatment of adult ALL patients. The results of these 
studies, that will be discussed in details below, showed the general idea that Chk1, Chk2 and 
Wee1 kinases are crucial for the leukemic cells not only to survive but also to sustain the 
intrinsic genetic instability that characterize this kind of hematological malignance. In line with 
the study of Sarmento and colleagues[73], in which the Chk1 kinase has been found over-
expressed and hyper-activated in T-ALL patients, we showed that the same kinase is highly 
expressed in our B-ALL patients cohort in comparison with its expression in mononuclear cells 
isolated form the peripheral blood of healthy donors. Moreover using immunohistochemistry 
we demonstrate that both the Chk1 and Chk2 pathways are hyper-activated in the tumor 
samples in comparison to normal tissue. On these bases we speculate that the inhibition of 
these kinases could mine the genetic stability of ALL cells, pushing the leukemic cells to 
progressively accumulate DNA damages up to a point of no return. For this reason we firstly 
evaluate the efficacy in single agent of the Chk1/Chk2 inhibitor, PF-0477736 on different cell 
lines and on primary cells isolated from adult B-ALL patients. The results of these experiments 
confirmed that the activities of these kinases are crucial for cell proliferation and cell survival. 
We demonstrate that the inhibition of both Chk1 and Chk2 promote the reduction of the cell 
viability, the activation of apoptosis and the modification of the expression of different 
elements of the G2/M pathway (both proteins and mRNA level). The consequences of 
Chk1/Chk2 inhibition firstly evaluated on different cells lines and on primary leukemic cells 
where then confirmed in vivo using mouse models. Despite the great response, in both primary 
and leukemic cell lines using PF-0477736 in single agent, we could not find any predictive 
markers of response. The sensitivity to the compound was not related with the different sub-
type of leukemia, with the basal expression of the target kinases, with the mutational status of 
p53 (marker of G1/S checkpoint functionality) and with the karyotypes. Similar results were 
obtained treating in single agent different cell lines and primary cells with the Chk1/Chk2 
inhibitor, LY2606368, and with the Wee-1 inhibitor, MK-1775. The consequences of Chk1/Chk2 
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and Wee1 inhibition on the cell cycle progression were then analyzed treating different cell 
lines respectively with LY2606368 and MK-1775 in single agent. The treatment with LY2606368 
progressively arrested the cells in S phase and, simultaneously, increased cell debris, supporting 
the hypothetical mechanism of death through “replication catastrophe”[76]. However in the 
inhibition of Wee1 increased the amount of cells in late S phase and in G2/M phase highlighting 
the potential mechanism of death through “mitotic catastrophe”. These data were supported 
by gene expression studies in which in both primary cells and leukemic cell lines the treatment 
with MK-1775 enhanced the expression of protein like, Cdc25C and the Cdc2-Cyclin B complex 
while repressed the expression of inhibitor the G2/M transition like Myt1. The consequence of 
the inhibition of the G2/M checkpoint after the treatment with MK-1775 was also analyzed in 
term of alterations of nuclear morphology. To this purpose primary cell were incubated with 
MK-1775 and the analyzed in light microscopy. The treated samples showed alterations in the 
morphology of the nucleus. Several DNA bridges, marker of mitotic alterations, were seen in all 
the treated samples but not in the controls. These alterations could not be detected on 
mononuclear cells isolated from healthy donors. To assess if the inhibition of the checkpoint 
kinase pathway could sensitize leukemic cells to the toxicity of different compound normally 
used in the clinic, different combination studies were performed. The Chk1/Chk2 inhibitor, 
LY2606368, and the Wee1 inhibitor, MK-1775, were combined with different Tyrosine Kinase 
inhibitors (imatinb, dasatinib and bosutinib), front line therapy for Philadelphia-positive B-ALL 
patients, and with the purine nucleoside analogue, clofarabine, used for the treatment of 
Philadelphia-negative B-ALL patients. The two checkpoint inhibitors deeply sensitized leukemic 
cell lines to the cytotoxicity of different compounds. The efficacy of the combinations was not 
only evaluated in term of reduction of the cell viability but also in term of induction of 
apoptosis (confirmed both by Western blots and Annexin V/Pi stainig) and induction of DNA 
damages (Western blots). The results found using different cell lines were then confirmed on 
primary cells isolated from the bone marrow and the peripheral blood of adult Philadelphia-
positive and negative B-ALL patients. Interestingly the combination between MK-1775 and 
clofarabine seems to be more efficacies in the p53 mutated cell lines than in the p53 wild type 
but this hypothesis was not evaluated on primary cells. Finally different class of checkpoint 
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kinase inhibitors were combined together in order to evaluate their interaction. On this 
purpose the Chk1/Chk2 inhibitor, PF-0477736, was combined together with the Wee1 inhibitor, 
MK-1775. This combination should drastically mine the integration of the genetic stability. 
Interestingly using sub-toxic concentration of both compounds, the combination strongly 
reduced the cell viability and synergistically increased the DNA damages in all the cell lines 
treated. Moreover the co-treatment deeply modified the cell cycle profile, arresting the cell in S 
phase and inhibited the proliferation in all the treated cell lines. 
In our opinion the preclinical data presented in this thesis are the basis for a future evaluation 
of this class of compound in clinical trials in the treatment of adult Acute Lymphoblastic 
Leukemia (ALL) patients. Although the mechanisms of action as well as the potential side 
effects of the checkpoint kinase inhibition must be better elucidate, we believe that the 
inhibition of Chk1/Chk2/Wee1 kinases could be a promising strategy to optimize the actual 
treatments and, consequently, to increase the cure rate of the patients. Finally future analyses 
must be performed to evaluate the potential synergistic effect of the combinations between 
checkpoint kinase inhibitors and other compound today used for the treatment of ALL patients. 
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